ArrayFilename	!Sample_title	!Sample_geo_accession	SLEDAI	!Sample_status	!Sample_submission_date	!Sample_last_update_date	!Sample_characteristics_ch1	!Sample_type	!Sample_channel_count	!Sample_source_name_ch1	!Sample_organism_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_characteristics_ch1	!Sample_treatment_protocol_ch1	!Sample_molecule_ch1	!Sample_extract_protocol_ch1	!Sample_label_ch1	!Sample_label_protocol_ch1	!Sample_taxid_ch1	!Sample_hyb_protocol	!Sample_scan_protocol	!Sample_description	!Sample_data_processing	!Sample_platform_id	!Sample_contact_name	!Sample_contact_email	!Sample_contact_phone	!Sample_contact_department	!Sample_contact_institute	!Sample_contact_address	!Sample_contact_city	!Sample_contact_state	!Sample_contact_zip/postal_code	!Sample_contact_country	!Sample_supplementary_file	!Sample_data_row_count	!Sample_relation	!series_matrix_table_begin	ID_REF	!series_matrix_table_endGSM2353111_A52084400939212081815420934610977.CEL	"SUBJ.0134, SLE, week52"	GSM2353111	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 55.8465753424657	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0134	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.26	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.268	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353111/suppl/GSM2353111_A52084400939212081815420934610977.CEL.gz	0			GSM2353111	GSM2353112_A52084400939235091415421177247062.CEL	"SUBJ.0371, SLE, baseline"	GSM2353112	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 57.6666666666666	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0371	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.962	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.253	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353112/suppl/GSM2353112_A52084400939235091415421177247062.CEL.gz	0	Reanalyzed by: GSM2352317		GSM2353112	GSM2353113_A52084400939234091415421177246960.CEL	"SUBJ.0371, SLE, week16"	GSM2353113	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 57.6666666666666	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0371	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.962	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.253	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353113/suppl/GSM2353113_A52084400939234091415421177246960.CEL.gz	0			GSM2353113	GSM2353114_A52084400939233091415421177246887.CEL	"SUBJ.0371, SLE, week52"	GSM2353114	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 57.6666666666666	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0371	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.962	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.253	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353114/suppl/GSM2353114_A52084400939233091415421177246887.CEL.gz	0			GSM2353114	GSM2353115_A52084400939920091515421247126490.CEL	"SUBJ.1051, SLE, baseline"	GSM2353115	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.775956284153	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1051	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.148	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353115/suppl/GSM2353115_A52084400939920091515421247126490.CEL.gz	0	Reanalyzed by: GSM2351455		GSM2353115	GSM2353116_A52084400940658100115421372840875.CEL	"SUBJ.1051, SLE, week16"	GSM2353116	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.775956284153	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1051	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.148	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353116/suppl/GSM2353116_A52084400940658100115421372840875.CEL.gz	0			GSM2353116	GSM2353117_A52084400940659100115421372840944.CEL	"SUBJ.1051, SLE, week52"	GSM2353117	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.775956284153	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1051	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.148	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353117/suppl/GSM2353117_A52084400940659100115421372840944.CEL.gz	0			GSM2353117	GSM2353118_A52084400940068100715421373649317.CEL	"SUBJ.1440, SLE, baseline"	GSM2353118	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.8551912568306	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1440	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353118/suppl/GSM2353118_A52084400940068100715421373649317.CEL.gz	0	Reanalyzed by: GSM2352594		GSM2353118	GSM2353119_A52084400940069100715421373649373.CEL	"SUBJ.1440, SLE, week16"	GSM2353119	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.8551912568306	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1440	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353119/suppl/GSM2353119_A52084400940069100715421373649373.CEL.gz	0			GSM2353119	GSM2353120_A52084400940068100715421373649274.CEL	"SUBJ.1440, SLE, week52"	GSM2353120	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.8551912568306	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1440	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353120/suppl/GSM2353120_A52084400940068100715421373649274.CEL.gz	0			GSM2353120	GSM2353121_A52084400939852091415421246947146.CEL	"SUBJ.1236, SLE, baseline"	GSM2353121	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.7732240437158	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1236	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 114	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.07	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.183	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353121/suppl/GSM2353121_A52084400939852091415421246947146.CEL.gz	0	Reanalyzed by: GSM2352171		GSM2353121	GSM2353122_A52084400939855091415421246947349.CEL	"SUBJ.1236, SLE, week16"	GSM2353122	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.7732240437158	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1236	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 114	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.07	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.183	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353122/suppl/GSM2353122_A52084400939855091415421246947349.CEL.gz	0			GSM2353122	GSM2353123_A52084400939852091415421246947144.CEL	"SUBJ.1236, SLE, week52"	GSM2353123	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.7732240437158	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1236	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 114	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.07	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.183	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353123/suppl/GSM2353123_A52084400939852091415421246947144.CEL.gz	0			GSM2353123	GSM2353124_A52084400939843091415421247047469.CEL	"SUBJ.1689, SLE, baseline"	GSM2353124	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.9726775956284	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1689	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 117	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.958	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.148	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353124/suppl/GSM2353124_A52084400939843091415421247047469.CEL.gz	0	Reanalyzed by: GSM2351296		GSM2353124	GSM2353125_A52084400939844091415421247047524.CEL	"SUBJ.1689, SLE, week16"	GSM2353125	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.9726775956284	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1689	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 117	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.958	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.148	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353125/suppl/GSM2353125_A52084400939844091415421247047524.CEL.gz	0			GSM2353125	GSM2353126_A52084400939845091415421247047581.CEL	"SUBJ.1689, SLE, week52"	GSM2353126	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.9726775956284	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1689	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 117	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.958	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.148	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353126/suppl/GSM2353126_A52084400939845091415421247047581.CEL.gz	0			GSM2353126	GSM2353127_A52084400939234091415421177246948.CEL	"SUBJ.0899, SLE, baseline"	GSM2353127	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.1068493150685	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0899	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.61	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.475	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353127/suppl/GSM2353127_A52084400939234091415421177246948.CEL.gz	0	Reanalyzed by: GSM2352157		GSM2353127	GSM2353128_A52084400939233091415421177246929.CEL	"SUBJ.0899, SLE, week16"	GSM2353128	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.1068493150685	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0899	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.61	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.475	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353128/suppl/GSM2353128_A52084400939233091415421177246929.CEL.gz	0			GSM2353128	GSM2353129_A52084400939115082215421026196701.CEL	"SUBJ.0899, SLE, week52"	GSM2353129	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.1068493150685	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0899	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.61	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.475	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353129/suppl/GSM2353129_A52084400939115082215421026196701.CEL.gz	0			GSM2353129	GSM2353130_A52084400939921091515421247126586.CEL	"SUBJ.1308, SLE, baseline"	GSM2353130	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.4109589041095	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1308	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 66	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.896	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.124	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353130/suppl/GSM2353130_A52084400939921091515421247126586.CEL.gz	0	Reanalyzed by: GSM2351677		GSM2353130	GSM2353131_A52084400940658100115421372840913.CEL	"SUBJ.1308, SLE, week16"	GSM2353131	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.4109589041095	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1308	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 66	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.896	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.124	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353131/suppl/GSM2353131_A52084400940658100115421372840913.CEL.gz	0			GSM2353131	GSM2353132_A52084400939846091515421247126609.CEL	"SUBJ.1308, SLE, week52"	GSM2353132	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.4109589041095	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1308	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 66	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.896	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.124	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353132/suppl/GSM2353132_A52084400939846091515421247126609.CEL.gz	0			GSM2353132	GSM2353133_A52084400939845091415421247047583.CEL	"SUBJ.0252, SLE, baseline"	GSM2353133	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.8438356164383	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0252	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 61	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.29	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.283	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353133/suppl/GSM2353133_A52084400939845091415421247047583.CEL.gz	0	Reanalyzed by: GSM2351537		GSM2353133	GSM2353134_A52084400939231091315421177046172.CEL	"SUBJ.0252, SLE, week16"	GSM2353134	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.8438356164383	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0252	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 61	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.29	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.283	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353134/suppl/GSM2353134_A52084400939231091315421177046172.CEL.gz	0			GSM2353134	GSM2353135_A52084400939842091415421247047371.CEL	"SUBJ.0252, SLE, week52"	GSM2353135	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.8438356164383	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0252	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 61	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.29	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.283	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353135/suppl/GSM2353135_A52084400939842091415421247047371.CEL.gz	0			GSM2353135	GSM2353136_A52084400939213081815420934611048.CEL	"SUBJ.0694, SLE, week16"	GSM2353136	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.7786885245901	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0694	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.729	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.084	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353136/suppl/GSM2353136_A52084400939213081815420934611048.CEL.gz	0			GSM2353136	GSM2353137_A52084400939907082115420971516261.CEL	"SUBJ.0694, SLE, week52"	GSM2353137	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.7786885245901	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0694	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.729	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.084	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353137/suppl/GSM2353137_A52084400939907082115420971516261.CEL.gz	0			GSM2353137	GSM2353138_A52084400939853091415421246947195.CEL	"SUBJ.0810, SLE, baseline"	GSM2353138	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.6958904109589	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0810	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.218	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353138/suppl/GSM2353138_A52084400939853091415421246947195.CEL.gz	0	Reanalyzed by: GSM2352442		GSM2353138	GSM2353139_A52084400939845091415421247047564.CEL	"SUBJ.0810, SLE, week16"	GSM2353139	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.6958904109589	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0810	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.218	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353139/suppl/GSM2353139_A52084400939845091415421247047564.CEL.gz	0			GSM2353139	GSM2353140_A52084400939843091415421247047457.CEL	"SUBJ.0810, SLE, week52"	GSM2353140	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.6958904109589	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0810	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.218	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353140/suppl/GSM2353140_A52084400939843091415421247047457.CEL.gz	0			GSM2353140	GSM2353141_A52084400940544091515421247226764.CEL	"SUBJ.0806, SLE, baseline"	GSM2353141	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.8958904109589	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0806	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.97	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.337	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353141/suppl/GSM2353141_A52084400940544091515421247226764.CEL.gz	0	Reanalyzed by: GSM2351360		GSM2353141	GSM2353142_A52084400940546091515421247226848.CEL	"SUBJ.0806, SLE, week16"	GSM2353142	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.8958904109589	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0806	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.97	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.337	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353142/suppl/GSM2353142_A52084400940546091515421247226848.CEL.gz	0			GSM2353142	GSM2353143_A52084400940546091515421247226896.CEL	"SUBJ.0806, SLE, week52"	GSM2353143	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.8958904109589	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0806	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.97	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.337	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353143/suppl/GSM2353143_A52084400940546091515421247226896.CEL.gz	0			GSM2353143	GSM2353144_A52084400939847091515421247126679.CEL	"SUBJ.0947, SLE, baseline"	GSM2353144	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.811475409836	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0947	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 124	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.252	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353144/suppl/GSM2353144_A52084400939847091515421247126679.CEL.gz	0	Reanalyzed by: GSM2352474		GSM2353144	GSM2353145_A52084400939920091515421247126521.CEL	"SUBJ.0947, SLE, week16"	GSM2353145	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.811475409836	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0947	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 124	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.252	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353145/suppl/GSM2353145_A52084400939920091515421247126521.CEL.gz	0			GSM2353145	GSM2353146_A52084400939846091515421247126654.CEL	"SUBJ.0947, SLE, week52"	GSM2353146	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.811475409836	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0947	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 124	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.252	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353146/suppl/GSM2353146_A52084400939846091515421247126654.CEL.gz	0			GSM2353146	GSM2353147_A52084400939232091415421177246845.CEL	"SUBJ.0063, SLE, baseline"	GSM2353147	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.8497267759562	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0063	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 50	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.772	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.203	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353147/suppl/GSM2353147_A52084400939232091415421177246845.CEL.gz	0	Reanalyzed by: GSM2352027		GSM2353147	GSM2353148_A52084400939235091415421177247105.CEL	"SUBJ.0063, SLE, week16"	GSM2353148	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.8497267759562	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0063	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 50	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.772	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.203	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353148/suppl/GSM2353148_A52084400939235091415421177247105.CEL.gz	0			GSM2353148	GSM2353149_A52084400939233091415421177246907.CEL	"SUBJ.0063, SLE, week52"	GSM2353149	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.8497267759562	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0063	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 50	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.772	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.203	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353149/suppl/GSM2353149_A52084400939233091415421177246907.CEL.gz	0			GSM2353149	GSM2353150_A52084400939214081815420934611089.CEL	"SUBJ.1121, SLE, baseline"	GSM2353150	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.6054794520548	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1121	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 120	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.235	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353150/suppl/GSM2353150_A52084400939214081815420934611089.CEL.gz	0	Reanalyzed by: GSM2352297		GSM2353150	GSM2353151_A52084400939212081815420934610999.CEL	"SUBJ.1121, SLE, week16"	GSM2353151	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.6054794520548	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1121	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 120	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.235	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353151/suppl/GSM2353151_A52084400939212081815420934610999.CEL.gz	0			GSM2353151	GSM2353152_A52084400939212081815420934610974.CEL	"SUBJ.1121, SLE, week52"	GSM2353152	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.6054794520548	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1121	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 120	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.235	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353152/suppl/GSM2353152_A52084400939212081815420934610974.CEL.gz	0			GSM2353152	GSM2353153_A52084400940070100715421373649394.CEL	"SUBJ.1419, SLE, baseline"	GSM2353153	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.972602739726	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1419	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.98	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.392	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353153/suppl/GSM2353153_A52084400940070100715421373649394.CEL.gz	0	Reanalyzed by: GSM2351174		GSM2353153	GSM2353154_A52084400940067100715421373649243.CEL	"SUBJ.1419, SLE, week16"	GSM2353154	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.972602739726	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1419	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 1.98	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.392	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353154/suppl/GSM2353154_A52084400940067100715421373649243.CEL.gz	0			GSM2353154	GSM2353155_A52084400939844091415421247047488.CEL	"SUBJ.0931, SLE, baseline"	GSM2353155	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.1890410958904	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0931	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.243	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353155/suppl/GSM2353155_A52084400939844091415421247047488.CEL.gz	0	Reanalyzed by: GSM2352690		GSM2353155	GSM2353156_A52084400939853091415421246947227.CEL	"SUBJ.0931, SLE, week16"	GSM2353156	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.1890410958904	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0931	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.243	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353156/suppl/GSM2353156_A52084400939853091415421246947227.CEL.gz	0			GSM2353156	GSM2353157_A52084400939235091415421177247082.CEL	"SUBJ.0931, SLE, week52"	GSM2353157	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.1890410958904	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0931	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.243	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353157/suppl/GSM2353157_A52084400939235091415421177247082.CEL.gz	0			GSM2353157	GSM2353158_A52084400939116082215421026196740.CEL	"SUBJ.0640, SLE, baseline"	GSM2353158	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.0931506849315	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0640	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 61	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.685	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.1	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353158/suppl/GSM2353158_A52084400939116082215421026196740.CEL.gz	0	Reanalyzed by: GSM2351694		GSM2353158	GSM2353159_A52084400939116082215421026196732.CEL	"SUBJ.0640, SLE, week16"	GSM2353159	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.0931506849315	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0640	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 61	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.685	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.1	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353159/suppl/GSM2353159_A52084400939116082215421026196732.CEL.gz	0			GSM2353159	GSM2353160_A52084400939114082215421026196647.CEL	"SUBJ.0640, SLE, week52"	GSM2353160	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.0931506849315	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0640	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 61	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.685	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.1	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353160/suppl/GSM2353160_A52084400939114082215421026196647.CEL.gz	0			GSM2353160	GSM2353161_A52084400939235091415421177247066.CEL	"SUBJ.1277, SLE, baseline"	GSM2353161	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.4219178082191	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1277	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 20	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.19	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.164	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353161/suppl/GSM2353161_A52084400939235091415421177247066.CEL.gz	0	Reanalyzed by: GSM2352640		GSM2353161	GSM2353162_A52084400940545091515421247226836.CEL	"SUBJ.1277, SLE, week16"	GSM2353162	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.4219178082191	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1277	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 20	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.19	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.164	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353162/suppl/GSM2353162_A52084400940545091515421247226836.CEL.gz	0			GSM2353162	GSM2353163_A52084400940544091515421247226771.CEL	"SUBJ.1277, SLE, week52"	GSM2353163	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.4219178082191	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1277	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 20	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.19	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.164	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353163/suppl/GSM2353163_A52084400940544091515421247226771.CEL.gz	0			GSM2353163	GSM2353164_A52084400939846091515421247126619.CEL	"SUBJ.1282, SLE, baseline"	GSM2353164	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.9945355191256	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1282	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 14	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.74	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.409	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353164/suppl/GSM2353164_A52084400939846091515421247126619.CEL.gz	0	Reanalyzed by: GSM2351784		GSM2353164	GSM2353165_A52084400940656100115421372840766.CEL	"SUBJ.1282, SLE, week16"	GSM2353165	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.9945355191256	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1282	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 14	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.74	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.409	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353165/suppl/GSM2353165_A52084400940656100115421372840766.CEL.gz	0			GSM2353165	GSM2353166_A52084400939920091515421247126504.CEL	"SUBJ.1282, SLE, week52"	GSM2353166	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.9945355191256	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1282	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 14	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.74	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.409	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353166/suppl/GSM2353166_A52084400939920091515421247126504.CEL.gz	0			GSM2353166	GSM2353167_A52084400940544091515421247226751.CEL	"SUBJ.1254, SLE, baseline"	GSM2353167	sledai_at_baseline: 24	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.5506849315068	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1254	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 37	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.08	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.234	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353167/suppl/GSM2353167_A52084400940544091515421247226751.CEL.gz	0	Reanalyzed by: GSM2351995		GSM2353167	GSM2353168_A52084400940545091515421247226792.CEL	"SUBJ.1254, SLE, week16"	GSM2353168	sledai_at_baseline: 24	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.5506849315068	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1254	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 37	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.08	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.234	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353168/suppl/GSM2353168_A52084400940545091515421247226792.CEL.gz	0			GSM2353168	GSM2353169_A52084400939845091415421247047565.CEL	"SUBJ.0310, SLE, baseline"	GSM2353169	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.6803278688524	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0310	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.17	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.169	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353169/suppl/GSM2353169_A52084400939845091415421247047565.CEL.gz	0	Reanalyzed by: GSM2352028		GSM2353169	GSM2353170_A52084400939496101415421438760388.CEL	"SUBJ.0310, SLE, week16"	GSM2353170	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.6803278688524	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0310	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.17	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.169	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353170/suppl/GSM2353170_A52084400939496101415421438760388.CEL.gz	0			GSM2353170	GSM2353171_A52084400939844091415421247047511.CEL	"SUBJ.0310, SLE, week52"	GSM2353171	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.6803278688524	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0310	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.17	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.169	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353171/suppl/GSM2353171_A52084400939844091415421247047511.CEL.gz	0			GSM2353171	GSM2353172_A52084400940659100115421372840932.CEL	"SUBJ.0260, SLE, week52"	GSM2353172	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.2383561643835	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0260	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.246	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353172/suppl/GSM2353172_A52084400940659100115421372840932.CEL.gz	0			GSM2353172	GSM2353173_A52084400939271081315420891403900.CEL	"SUBJ.0920, SLE, baseline"	GSM2353173	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.983606557377	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0920	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.495	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.076	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353173/suppl/GSM2353173_A52084400939271081315420891403900.CEL.gz	0	Reanalyzed by: GSM2352422		GSM2353173	GSM2353174_A52084400939272081315420891403986.CEL	"SUBJ.0920, SLE, week16"	GSM2353174	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.983606557377	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0920	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.495	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.076	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353174/suppl/GSM2353174_A52084400939272081315420891403986.CEL.gz	0			GSM2353174	GSM2353175_A52084400939213081815420934611054.CEL	"SUBJ.0920, SLE, week52"	GSM2353175	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.983606557377	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0920	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.495	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.076	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353175/suppl/GSM2353175_A52084400939213081815420934611054.CEL.gz	0			GSM2353175	GSM2353176_A52084400939212081815420934610959.CEL	"SUBJ.1299, SLE, baseline"	GSM2353176	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.0739726027397	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1299	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 251	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.83	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.103	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353176/suppl/GSM2353176_A52084400939212081815420934610959.CEL.gz	0	Reanalyzed by: GSM2352335		GSM2353176	GSM2353177_A52084400939215081815420934611164.CEL	"SUBJ.1299, SLE, week16"	GSM2353177	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.0739726027397	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1299	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 251	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.83	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.103	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353177/suppl/GSM2353177_A52084400939215081815420934611164.CEL.gz	0			GSM2353177	GSM2353178_A52084400939213081815420934611035.CEL	"SUBJ.1299, SLE, week52"	GSM2353178	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.0739726027397	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1299	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 251	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.83	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.103	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353178/suppl/GSM2353178_A52084400939213081815420934611035.CEL.gz	0			GSM2353178	GSM2353179_A52084400939853091415421246947198.CEL	"SUBJ.0454, SLE, baseline"	GSM2353179	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.6994535519125	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0454	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 150	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.521	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.123	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353179/suppl/GSM2353179_A52084400939853091415421246947198.CEL.gz	0	Reanalyzed by: GSM2351492		GSM2353179	GSM2353180_A52084400939234091415421177246972.CEL	"SUBJ.0454, SLE, week16"	GSM2353180	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.6994535519125	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0454	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 150	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.521	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.123	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353180/suppl/GSM2353180_A52084400939234091415421177246972.CEL.gz	0			GSM2353180	GSM2353181_A52084400939854091415421246947266.CEL	"SUBJ.0454, SLE, week52"	GSM2353181	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.6994535519125	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0454	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 150	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.521	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.123	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353181/suppl/GSM2353181_A52084400939854091415421246947266.CEL.gz	0			GSM2353181	GSM2353182_A52084400939113082215421026196586.CEL	"SUBJ.0603, SLE, baseline"	GSM2353182	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.9672131147541	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0603	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 47	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.191	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353182/suppl/GSM2353182_A52084400939113082215421026196586.CEL.gz	0	Reanalyzed by: GSM2352487		GSM2353182	GSM2353183_A52084400939114082215421026196645.CEL	"SUBJ.0603, SLE, week16"	GSM2353183	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.9672131147541	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0603	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 47	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.191	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353183/suppl/GSM2353183_A52084400939114082215421026196645.CEL.gz	0			GSM2353183	GSM2353184_A52084400939116082215421026196738.CEL	"SUBJ.0603, SLE, week52"	GSM2353184	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.9672131147541	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0603	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 47	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.02	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.191	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353184/suppl/GSM2353184_A52084400939116082215421026196738.CEL.gz	0			GSM2353184	GSM2353185_A52084400939845091415421247047558.CEL	"SUBJ.0015, SLE, baseline"	GSM2353185	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.9534246575342	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0015	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.802	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.147	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353185/suppl/GSM2353185_A52084400939845091415421247047558.CEL.gz	0	Reanalyzed by: GSM2351341		GSM2353185	GSM2353186_A52084400939845091415421247047580.CEL	"SUBJ.0015, SLE, week16"	GSM2353186	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.9534246575342	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0015	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.802	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.147	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353186/suppl/GSM2353186_A52084400939845091415421247047580.CEL.gz	0			GSM2353186	GSM2353187_A52084400939842091415421247047400.CEL	"SUBJ.0015, SLE, week52"	GSM2353187	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.9534246575342	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0015	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.802	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.147	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353187/suppl/GSM2353187_A52084400939842091415421247047400.CEL.gz	0			GSM2353187	GSM2353188_A52084400939847091515421247126673.CEL	"SUBJ.1160, SLE, baseline"	GSM2353188	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 64.7835616438356	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1160	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.33	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353188/suppl/GSM2353188_A52084400939847091515421247126673.CEL.gz	0	Reanalyzed by: GSM2351938		GSM2353188	GSM2353189_A52084400939921091515421247126569.CEL	"SUBJ.1160, SLE, week16"	GSM2353189	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 64.7835616438356	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1160	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.33	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353189/suppl/GSM2353189_A52084400939921091515421247126569.CEL.gz	0			GSM2353189	GSM2353190_A52084400939847091515421247126671.CEL	"SUBJ.1160, SLE, week52"	GSM2353190	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 64.7835616438356	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1160	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.33	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353190/suppl/GSM2353190_A52084400939847091515421247126671.CEL.gz	0			GSM2353190	GSM2353191_A52084400939855091415421246947331.CEL	"SUBJ.0833, SLE, baseline"	GSM2353191	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.131506849315	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0833	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.809	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.404	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353191/suppl/GSM2353191_A52084400939855091415421246947331.CEL.gz	0	Reanalyzed by: GSM2352316		GSM2353191	GSM2353192_A52084400939854091415421246947271.CEL	"SUBJ.0833, SLE, week16"	GSM2353192	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.131506849315	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0833	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.809	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.404	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353192/suppl/GSM2353192_A52084400939854091415421246947271.CEL.gz	0			GSM2353192	GSM2353193_A52084400939855091415421246947314.CEL	"SUBJ.0833, SLE, week52"	GSM2353193	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.131506849315	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0833	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.809	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.404	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353193/suppl/GSM2353193_A52084400939855091415421246947314.CEL.gz	0			GSM2353193	GSM2353194_A52084400939842091415421247047389.CEL	"SUBJ.0254, SLE, baseline"	GSM2353194	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.2027397260274	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0254	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 129	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.155	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353194/suppl/GSM2353194_A52084400939842091415421247047389.CEL.gz	0	Reanalyzed by: GSM2352301		GSM2353194	GSM2353195_A52084400939231091315421177046217.CEL	"SUBJ.0254, SLE, week16"	GSM2353195	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.2027397260274	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0254	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 129	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.155	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353195/suppl/GSM2353195_A52084400939231091315421177046217.CEL.gz	0			GSM2353195	GSM2353196_A52084400939842091415421247047401.CEL	"SUBJ.0254, SLE, week52"	GSM2353196	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.2027397260274	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0254	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 129	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.155	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353196/suppl/GSM2353196_A52084400939842091415421247047401.CEL.gz	0			GSM2353196	GSM2353197_A52084400939234091415421177246973.CEL	"SUBJ.0299, SLE, baseline"	GSM2353197	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.6602739726027	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0299	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 127	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.898	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.158	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353197/suppl/GSM2353197_A52084400939234091415421177246973.CEL.gz	0	Reanalyzed by: GSM2351954		GSM2353197	GSM2353198_A52084400939232091415421177246830.CEL	"SUBJ.0299, SLE, week16"	GSM2353198	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.6602739726027	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0299	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 127	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.898	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.158	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353198/suppl/GSM2353198_A52084400939232091415421177246830.CEL.gz	0			GSM2353198	GSM2353199_A52084400939232091415421177246852.CEL	"SUBJ.0299, SLE, week52"	GSM2353199	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.6602739726027	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0299	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 127	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.898	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.158	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353199/suppl/GSM2353199_A52084400939232091415421177246852.CEL.gz	0			GSM2353199	GSM2353200_A52084400939272081315420891403990.CEL	"SUBJ.0203, SLE, baseline"	GSM2353200	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.4520547945205	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0203	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.187	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353200/suppl/GSM2353200_A52084400939272081315420891403990.CEL.gz	0	Reanalyzed by: GSM2351748		GSM2353200	GSM2353201_A52084400939272081315420891403974.CEL	"SUBJ.0203, SLE, week16"	GSM2353201	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.4520547945205	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0203	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.187	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353201/suppl/GSM2353201_A52084400939272081315420891403974.CEL.gz	0			GSM2353201	GSM2353202_A52084400939213081815420934611031.CEL	"SUBJ.0203, SLE, week52"	GSM2353202	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.4520547945205	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0203	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.187	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353202/suppl/GSM2353202_A52084400939213081815420934611031.CEL.gz	0			GSM2353202	GSM2353203_A52084400939472101415421438760276.CEL	"SUBJ.0999, SLE, baseline"	GSM2353203	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.6821917808219	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0999	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.7	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.4	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353203/suppl/GSM2353203_A52084400939472101415421438760276.CEL.gz	0	Reanalyzed by: GSM2350982		GSM2353203	GSM2353204_A52084400940656100115421372840778.CEL	"SUBJ.0999, SLE, week16"	GSM2353204	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.6821917808219	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0999	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.7	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.4	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353204/suppl/GSM2353204_A52084400940656100115421372840778.CEL.gz	0			GSM2353204	GSM2353205_A52084400939846091515421247126635.CEL	"SUBJ.0999, SLE, week52"	GSM2353205	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.6821917808219	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0999	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.7	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.4	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353205/suppl/GSM2353205_A52084400939846091515421247126635.CEL.gz	0			GSM2353205	GSM2353206_A52084400939269081315420891403804.CEL	"SUBJ.1492, SLE, baseline"	GSM2353206	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.6191780821917	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1492	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.159	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353206/suppl/GSM2353206_A52084400939269081315420891403804.CEL.gz	0	Reanalyzed by: GSM2351519		GSM2353206	GSM2353207_A52084400939272081315420891403944.CEL	"SUBJ.1492, SLE, week16"	GSM2353207	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.6191780821917	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1492	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.159	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353207/suppl/GSM2353207_A52084400939272081315420891403944.CEL.gz	0			GSM2353207	GSM2353208_A52084400939269081315420891403796.CEL	"SUBJ.1492, SLE, week52"	GSM2353208	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.6191780821917	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1492	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.159	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353208/suppl/GSM2353208_A52084400939269081315420891403796.CEL.gz	0			GSM2353208	GSM2353209_A52084400939231091315421177046214.CEL	"SUBJ.0579, SLE, baseline"	GSM2353209	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.6639344262295	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0579	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 197	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.823	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.13	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353209/suppl/GSM2353209_A52084400939231091315421177046214.CEL.gz	0	Reanalyzed by: GSM2351946		GSM2353209	GSM2353210_A52084400939845091415421247047570.CEL	"SUBJ.0579, SLE, week16"	GSM2353210	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.6639344262295	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0579	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 197	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.823	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.13	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353210/suppl/GSM2353210_A52084400939845091415421247047570.CEL.gz	0			GSM2353210	GSM2353211_A52084400939231091315421177046196.CEL	"SUBJ.0579, SLE, week52"	GSM2353211	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.6639344262295	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0579	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 197	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.823	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.13	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353211/suppl/GSM2353211_A52084400939231091315421177046196.CEL.gz	0			GSM2353211	GSM2353212_A52084400939213081815420934611039.CEL	"SUBJ.1686, SLE, baseline"	GSM2353212	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.7978142076502	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1686	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.673	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.112	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353212/suppl/GSM2353212_A52084400939213081815420934611039.CEL.gz	0	Reanalyzed by: GSM2351028		GSM2353212	GSM2353213_A52084400939213081815420934611058.CEL	"SUBJ.1686, SLE, week16"	GSM2353213	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.7978142076502	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1686	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.673	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.112	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353213/suppl/GSM2353213_A52084400939213081815420934611058.CEL.gz	0			GSM2353213	GSM2353214_A52084400939212081815420934610961.CEL	"SUBJ.1686, SLE, week52"	GSM2353214	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.7978142076502	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1686	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.673	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.112	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353214/suppl/GSM2353214_A52084400939212081815420934610961.CEL.gz	0			GSM2353214	GSM2353215_A52084400939215081815420934611151.CEL	"SUBJ.1773, SLE, baseline"	GSM2353215	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.5917808219178	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1773	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353215/suppl/GSM2353215_A52084400939215081815420934611151.CEL.gz	0	Reanalyzed by: GSM2351498		GSM2353215	GSM2353216_A52084400939215081815420934611154.CEL	"SUBJ.1773, SLE, week16"	GSM2353216	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.5917808219178	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1773	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353216/suppl/GSM2353216_A52084400939215081815420934611154.CEL.gz	0			GSM2353216	GSM2353217_A52084400939214081815420934611109.CEL	"SUBJ.1773, SLE, week52"	GSM2353217	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 62.5917808219178	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1773	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353217/suppl/GSM2353217_A52084400939214081815420934611109.CEL.gz	0			GSM2353217	GSM2353218_A52084400939842091415421247047377.CEL	"SUBJ.0489, SLE, baseline"	GSM2353218	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.8958904109589	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0489	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 41	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.814	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.241	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353218/suppl/GSM2353218_A52084400939842091415421247047377.CEL.gz	0	Reanalyzed by: GSM2352670		GSM2353218	GSM2353219_A52084400939233091415421177246908.CEL	"SUBJ.0489, SLE, week16"	GSM2353219	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.8958904109589	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0489	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 41	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.814	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.241	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353219/suppl/GSM2353219_A52084400939233091415421177246908.CEL.gz	0			GSM2353219	GSM2353220_A52084400939233091415421177246894.CEL	"SUBJ.0489, SLE, week52"	GSM2353220	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.8958904109589	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0489	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 41	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.814	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.241	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353220/suppl/GSM2353220_A52084400939233091415421177246894.CEL.gz	0			GSM2353220	GSM2353221_A52084400939843091415421247047426.CEL	"SUBJ.0897, SLE, baseline"	GSM2353221	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.3780821917808	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0897	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.362	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353221/suppl/GSM2353221_A52084400939843091415421247047426.CEL.gz	0	Reanalyzed by: GSM2352280		GSM2353221	GSM2353222_A52084400939855091415421246947302.CEL	"SUBJ.0897, SLE, week16"	GSM2353222	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.3780821917808	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0897	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.362	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353222/suppl/GSM2353222_A52084400939855091415421246947302.CEL.gz	0			GSM2353222	GSM2353223_A52084400939855091415421246947312.CEL	"SUBJ.0897, SLE, week52"	GSM2353223	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.3780821917808	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0897	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.362	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353223/suppl/GSM2353223_A52084400939855091415421246947312.CEL.gz	0			GSM2353223	GSM2353224_A52084400940546091515421247226871.CEL	"SUBJ.0688, SLE, baseline"	GSM2353224	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.9480874316939	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0688	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 63	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.258	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353224/suppl/GSM2353224_A52084400940546091515421247226871.CEL.gz	0	Reanalyzed by: GSM2351582		GSM2353224	GSM2353225_A52084400940548091515421247226921.CEL	"SUBJ.0688, SLE, week16"	GSM2353225	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.9480874316939	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0688	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 63	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.258	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353225/suppl/GSM2353225_A52084400940548091515421247226921.CEL.gz	0			GSM2353225	GSM2353226_A52084400940544091515421247226736.CEL	"SUBJ.0688, SLE, week52"	GSM2353226	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.9480874316939	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0688	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 63	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.258	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353226/suppl/GSM2353226_A52084400940544091515421247226736.CEL.gz	0			GSM2353226	GSM2353227_A52084400939854091415421246947256.CEL	"SUBJ.0645, SLE, week16"	GSM2353227	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.9071038251366	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0645	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.816	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353227/suppl/GSM2353227_A52084400939854091415421246947256.CEL.gz	0			GSM2353227	GSM2353228_A52084400939853091415421246947207.CEL	"SUBJ.0645, SLE, week52"	GSM2353228	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.9071038251366	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0645	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.816	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353228/suppl/GSM2353228_A52084400939853091415421246947207.CEL.gz	0			GSM2353228	GSM2353229_A52084400939843091415421247047444.CEL	"SUBJ.1612, SLE, baseline"	GSM2353229	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8333333333333	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1612	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.81	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.162	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353229/suppl/GSM2353229_A52084400939843091415421247047444.CEL.gz	0	Reanalyzed by: GSM2351119		GSM2353229	GSM2353230_A52084400939844091415421247047532.CEL	"SUBJ.1612, SLE, week16"	GSM2353230	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8333333333333	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1612	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.81	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.162	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353230/suppl/GSM2353230_A52084400939844091415421247047532.CEL.gz	0			GSM2353230	GSM2353231_A52084400939233091415421177246919.CEL	"SUBJ.1612, SLE, week52"	GSM2353231	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8333333333333	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1612	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.81	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.162	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353231/suppl/GSM2353231_A52084400939233091415421177246919.CEL.gz	0			GSM2353231	GSM2353232_A52084400939231091315421177046194.CEL	"SUBJ.0061, SLE, baseline"	GSM2353232	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 61.0328767123287	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0061	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: asian	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 47	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.286	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353232/suppl/GSM2353232_A52084400939231091315421177046194.CEL.gz	0	Reanalyzed by: GSM2351686		GSM2353232	GSM2353233_A52084400939842091415421247047404.CEL	"SUBJ.0061, SLE, week16"	GSM2353233	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 61.0328767123287	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0061	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: asian	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 47	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.286	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353233/suppl/GSM2353233_A52084400939842091415421247047404.CEL.gz	0			GSM2353233	GSM2353234_A52084400939230091315421177046068.CEL	"SUBJ.0061, SLE, week52"	GSM2353234	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 61.0328767123287	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0061	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: asian	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 47	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.286	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353234/suppl/GSM2353234_A52084400939230091315421177046068.CEL.gz	0			GSM2353234	GSM2353235_A52084400939235091415421177247108.CEL	"SUBJ.1111, SLE, baseline"	GSM2353235	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.5616438356164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1111	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.213	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353235/suppl/GSM2353235_A52084400939235091415421177247108.CEL.gz	0	Reanalyzed by: GSM2351046		GSM2353235	GSM2353236_A52084400939232091415421177246837.CEL	"SUBJ.1111, SLE, week16"	GSM2353236	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.5616438356164	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1111	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.213	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353236/suppl/GSM2353236_A52084400939232091415421177246837.CEL.gz	0			GSM2353236	GSM2353237_A52084400939235091415421177247061.CEL	"SUBJ.1111, SLE, week52"	GSM2353237	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.5616438356164	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1111	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 38	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.36	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.213	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353237/suppl/GSM2353237_A52084400939235091415421177247061.CEL.gz	0			GSM2353237	GSM2353238_A52084400939920091515421247126509.CEL	"SUBJ.1203, SLE, baseline"	GSM2353238	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 18.7377049180327	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1203	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.775	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353238/suppl/GSM2353238_A52084400939920091515421247126509.CEL.gz	0	Reanalyzed by: GSM2351432		GSM2353238	GSM2353239_A52084400940656100115421372840751.CEL	"SUBJ.1203, SLE, week16"	GSM2353239	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 18.7377049180327	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1203	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.775	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353239/suppl/GSM2353239_A52084400940656100115421372840751.CEL.gz	0			GSM2353239	GSM2353240_A52084400940659100115421372840963.CEL	"SUBJ.1203, SLE, week52"	GSM2353240	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 18.7377049180327	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1203	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.775	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353240/suppl/GSM2353240_A52084400940659100115421372840963.CEL.gz	0			GSM2353240	GSM2353241_A52084400940548091515421247226947.CEL	"SUBJ.1421, SLE, baseline"	GSM2353241	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.9262295081967	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1421	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.21	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.187	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353241/suppl/GSM2353241_A52084400940548091515421247226947.CEL.gz	0	Reanalyzed by: GSM2352499		GSM2353241	GSM2353242_A52084400940546091515421247226892.CEL	"SUBJ.1421, SLE, week16"	GSM2353242	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.9262295081967	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1421	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.21	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.187	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353242/suppl/GSM2353242_A52084400940546091515421247226892.CEL.gz	0			GSM2353242	GSM2353243_A52084400940548091515421247226938.CEL	"SUBJ.1421, SLE, week52"	GSM2353243	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.9262295081967	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1421	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.21	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.187	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353243/suppl/GSM2353243_A52084400940548091515421247226938.CEL.gz	0			GSM2353243	GSM2353244_A52084400939472101415421438775718.CEL	"SUBJ.0885, SLE, baseline"	GSM2353244	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 19.4328767123287	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0885	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: multiple	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 190	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.191	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353244/suppl/GSM2353244_A52084400939472101415421438775718.CEL.gz	0	Reanalyzed by: GSM2351329		GSM2353244	GSM2353245_A52084400940657100115421372840858.CEL	"SUBJ.0885, SLE, week16"	GSM2353245	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 19.4328767123287	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0885	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: multiple	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 190	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.191	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353245/suppl/GSM2353245_A52084400940657100115421372840858.CEL.gz	0			GSM2353245	GSM2353246_A52084400940657100115421372840830.CEL	"SUBJ.0885, SLE, week52"	GSM2353246	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 19.4328767123287	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0885	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: multiple	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 190	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.191	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353246/suppl/GSM2353246_A52084400940657100115421372840830.CEL.gz	0			GSM2353246	GSM2353247_A52084400939853091415421246947196.CEL	"SUBJ.1340, SLE, baseline"	GSM2353247	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.8547945205479	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1340	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.831	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.108	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353247/suppl/GSM2353247_A52084400939853091415421246947196.CEL.gz	0	Reanalyzed by: GSM2352668		GSM2353247	GSM2353248_A52084400939852091415421246947142.CEL	"SUBJ.1340, SLE, week16"	GSM2353248	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.8547945205479	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1340	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.831	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.108	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353248/suppl/GSM2353248_A52084400939852091415421246947142.CEL.gz	0			GSM2353248	GSM2353249_A52084400939855091415421246947309.CEL	"SUBJ.1340, SLE, week52"	GSM2353249	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.8547945205479	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1340	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.831	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.108	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353249/suppl/GSM2353249_A52084400939855091415421246947309.CEL.gz	0			GSM2353249	GSM2353250_A52084400940659100115421372840934.CEL	"SUBJ.0792, SLE, baseline"	GSM2353250	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8989071038251	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0792	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 100	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.847	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353250/suppl/GSM2353250_A52084400940659100115421372840934.CEL.gz	0	Reanalyzed by: GSM2351091		GSM2353250	GSM2353251_A52084400940659100115421372840938.CEL	"SUBJ.0792, SLE, week16"	GSM2353251	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8989071038251	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0792	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 100	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.847	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353251/suppl/GSM2353251_A52084400940659100115421372840938.CEL.gz	0			GSM2353251	GSM2353252_A52084400940658100115421372840891.CEL	"SUBJ.0792, SLE, week52"	GSM2353252	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8989071038251	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0792	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 100	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.847	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353252/suppl/GSM2353252_A52084400940658100115421372840891.CEL.gz	0			GSM2353252	GSM2353253_A52084400939855091415421246947328.CEL	"SUBJ.0821, SLE, baseline"	GSM2353253	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.2082191780822	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0821	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.663	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.104	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353253/suppl/GSM2353253_A52084400939855091415421246947328.CEL.gz	0	Reanalyzed by: GSM2351333		GSM2353253	GSM2353254_A52084400939854091415421246947270.CEL	"SUBJ.0821, SLE, week16"	GSM2353254	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.2082191780822	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0821	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.663	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.104	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353254/suppl/GSM2353254_A52084400939854091415421246947270.CEL.gz	0			GSM2353254	GSM2353255_A52084400939845091415421247047560.CEL	"SUBJ.0821, SLE, week52"	GSM2353255	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.2082191780822	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0821	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.663	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.104	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353255/suppl/GSM2353255_A52084400939845091415421247047560.CEL.gz	0			GSM2353255	GSM2353256_A52084400940069100715421373649354.CEL	"SUBJ.0428, SLE, baseline"	GSM2353256	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.2767123287671	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0428	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 184	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.63	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.074	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353256/suppl/GSM2353256_A52084400940069100715421373649354.CEL.gz	0	Reanalyzed by: GSM2351678		GSM2353256	GSM2353257_A52084400940081100815421437950407.CEL	"SUBJ.0428, SLE, week16"	GSM2353257	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.2767123287671	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0428	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 184	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.63	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.074	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353257/suppl/GSM2353257_A52084400940081100815421437950407.CEL.gz	0			GSM2353257	GSM2353258_A52084400940082100815421437950468.CEL	"SUBJ.0428, SLE, week52"	GSM2353258	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.2767123287671	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0428	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 184	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.63	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.074	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353258/suppl/GSM2353258_A52084400940082100815421437950468.CEL.gz	0			GSM2353258	GSM2353259_A52084400940549091515421247348551.CEL	"SUBJ.0720, SLE, baseline"	GSM2353259	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.9753424657534	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0720	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 111	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.706	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.158	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353259/suppl/GSM2353259_A52084400940549091515421247348551.CEL.gz	0	Reanalyzed by: GSM2352378		GSM2353259	GSM2353260_A52084400940549091515421247348539.CEL	"SUBJ.0720, SLE, week16"	GSM2353260	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.9753424657534	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0720	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 111	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.706	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.158	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353260/suppl/GSM2353260_A52084400940549091515421247348539.CEL.gz	0			GSM2353260	GSM2353261_A52084400939232091415421177246826.CEL	"SUBJ.0720, SLE, week52"	GSM2353261	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.9753424657534	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0720	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 111	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.706	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.158	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353261/suppl/GSM2353261_A52084400939232091415421177246826.CEL.gz	0			GSM2353261	GSM2353262_A52084400939116082215421026196729.CEL	"SUBJ.0133, SLE, baseline"	GSM2353262	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.3397260273972	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0133	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.759	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.243	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353262/suppl/GSM2353262_A52084400939116082215421026196729.CEL.gz	0	Reanalyzed by: GSM2351164		GSM2353262	GSM2353263_A52084400939114082215421026196602.CEL	"SUBJ.0133, SLE, week16"	GSM2353263	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.3397260273972	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0133	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.759	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.243	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353263/suppl/GSM2353263_A52084400939114082215421026196602.CEL.gz	0			GSM2353263	GSM2353264_A52084400939113082215421026196579.CEL	"SUBJ.0133, SLE, week52"	GSM2353264	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 29.3397260273972	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0133	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.759	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.243	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353264/suppl/GSM2353264_A52084400939113082215421026196579.CEL.gz	0			GSM2353264	GSM2353265_A52084400940656100115421372840753.CEL	"SUBJ.1294, SLE, baseline"	GSM2353265	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8169398907103	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1294	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 114	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.798	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.144	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353265/suppl/GSM2353265_A52084400940656100115421372840753.CEL.gz	0	Reanalyzed by: GSM2352583		GSM2353265	GSM2353266_A52084400940658100115421372840877.CEL	"SUBJ.1294, SLE, week16"	GSM2353266	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8169398907103	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1294	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 114	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.798	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.144	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353266/suppl/GSM2353266_A52084400940658100115421372840877.CEL.gz	0			GSM2353266	GSM2353267_A52084400940656100115421372840765.CEL	"SUBJ.1294, SLE, week52"	GSM2353267	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 36.8169398907103	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1294	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 114	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.798	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.144	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353267/suppl/GSM2353267_A52084400940656100115421372840765.CEL.gz	0			GSM2353267	GSM2353268_A52084400939114082215421026196631.CEL	"SUBJ.0292, SLE, baseline"	GSM2353268	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.8821917808219	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0292	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.27	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.221	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353268/suppl/GSM2353268_A52084400939114082215421026196631.CEL.gz	0	Reanalyzed by: GSM2350993		GSM2353268	GSM2353269_A52084400939116082215421026196722.CEL	"SUBJ.0292, SLE, week16"	GSM2353269	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.8821917808219	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0292	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.27	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.221	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353269/suppl/GSM2353269_A52084400939116082215421026196722.CEL.gz	0			GSM2353269	GSM2353270_A52084400939114082215421026196601.CEL	"SUBJ.0292, SLE, week52"	GSM2353270	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.8821917808219	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0292	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.27	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.221	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353270/suppl/GSM2353270_A52084400939114082215421026196601.CEL.gz	0			GSM2353270	GSM2353271_A52084400939233091415421177246892.CEL	"SUBJ.1084, SLE, baseline"	GSM2353271	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.3534246575342	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1084	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.26	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.264	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353271/suppl/GSM2353271_A52084400939233091415421177246892.CEL.gz	0	Reanalyzed by: GSM2352047		GSM2353271	GSM2353272_A52084400939234091415421177246984.CEL	"SUBJ.1084, SLE, week16"	GSM2353272	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.3534246575342	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1084	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.26	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.264	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353272/suppl/GSM2353272_A52084400939234091415421177246984.CEL.gz	0			GSM2353272	GSM2353273_A52084400939496101415421438760383.CEL	"SUBJ.1084, SLE, week52"	GSM2353273	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.3534246575342	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1084	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.26	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.264	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353273/suppl/GSM2353273_A52084400939496101415421438760383.CEL.gz	0			GSM2353273	GSM2353274_A52084400939230091315421177046059.CEL	"SUBJ.0364, SLE, baseline"	GSM2353274	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.3917808219178	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0364	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353274/suppl/GSM2353274_A52084400939230091315421177046059.CEL.gz	0	Reanalyzed by: GSM2351830		GSM2353274	GSM2353275_A52084400939842091415421247047384.CEL	"SUBJ.0364, SLE, week16"	GSM2353275	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.3917808219178	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0364	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353275/suppl/GSM2353275_A52084400939842091415421247047384.CEL.gz	0			GSM2353275	GSM2353276_A52084400939228091315421177045860.CEL	"SUBJ.0364, SLE, week52"	GSM2353276	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.3917808219178	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0364	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.088	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353276/suppl/GSM2353276_A52084400939228091315421177045860.CEL.gz	0			GSM2353276	GSM2353277_A52084400939116082215421026196748.CEL	"SUBJ.1687, SLE, baseline"	GSM2353277	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.724043715847	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1687	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.4	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.231	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353277/suppl/GSM2353277_A52084400939116082215421026196748.CEL.gz	0	Reanalyzed by: GSM2352021		GSM2353277	GSM2353278_A52084400939116082215421026196736.CEL	"SUBJ.1687, SLE, week16"	GSM2353278	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.724043715847	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1687	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.4	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.231	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353278/suppl/GSM2353278_A52084400939116082215421026196736.CEL.gz	0			GSM2353278	GSM2353279_A52084400939116082215421026196743.CEL	"SUBJ.1687, SLE, week52"	GSM2353279	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.724043715847	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1687	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.4	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.231	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353279/suppl/GSM2353279_A52084400939116082215421026196743.CEL.gz	0			GSM2353279	GSM2353280_A52084400939852091415421246947158.CEL	"SUBJ.1222, SLE, baseline"	GSM2353280	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 66.7622950819672	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1222	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.967	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.189	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353280/suppl/GSM2353280_A52084400939852091415421246947158.CEL.gz	0	Reanalyzed by: GSM2352260		GSM2353280	GSM2353281_A52084400939852091415421246947163.CEL	"SUBJ.1222, SLE, week16"	GSM2353281	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 66.7622950819672	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1222	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.967	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.189	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353281/suppl/GSM2353281_A52084400939852091415421246947163.CEL.gz	0			GSM2353281	GSM2353282_A52084400939852091415421246947167.CEL	"SUBJ.1222, SLE, week52"	GSM2353282	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 66.7622950819672	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1222	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.967	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.189	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353282/suppl/GSM2353282_A52084400939852091415421246947167.CEL.gz	0			GSM2353282	GSM2353283_A52084400940659100115421372840935.CEL	"SUBJ.1806, SLE, baseline"	GSM2353283	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.7404371584699	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1806	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 24	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.17	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.171	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353283/suppl/GSM2353283_A52084400940659100115421372840935.CEL.gz	0	Reanalyzed by: GSM2351444		GSM2353283	GSM2353284_A52084400940656100115421372840764.CEL	"SUBJ.1806, SLE, week16"	GSM2353284	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.7404371584699	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1806	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 24	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.17	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.171	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353284/suppl/GSM2353284_A52084400940656100115421372840764.CEL.gz	0			GSM2353284	GSM2353285_A52084400940657100115421372840818.CEL	"SUBJ.1806, SLE, week52"	GSM2353285	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.7404371584699	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1806	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 24	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.17	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.171	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353285/suppl/GSM2353285_A52084400940657100115421372840818.CEL.gz	0			GSM2353285	GSM2353286_A52084400939215081815420934611133.CEL	"SUBJ.1543, SLE, baseline"	GSM2353286	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.6082191780822	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1543	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 74	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.38	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353286/suppl/GSM2353286_A52084400939215081815420934611133.CEL.gz	0	Reanalyzed by: GSM2351632		GSM2353286	GSM2353287_A52084400939215081815420934611141.CEL	"SUBJ.1543, SLE, week16"	GSM2353287	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.6082191780822	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1543	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 74	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.38	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353287/suppl/GSM2353287_A52084400939215081815420934611141.CEL.gz	0			GSM2353287	GSM2353288_A52084400939215081815420934611140.CEL	"SUBJ.1543, SLE, week52"	GSM2353288	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.6082191780822	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1543	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 74	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.03	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.38	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353288/suppl/GSM2353288_A52084400939215081815420934611140.CEL.gz	0			GSM2353288	GSM2353289_A52084400939114082215421026196617.CEL	"SUBJ.0660, SLE, baseline"	GSM2353289	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.9699453551912	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0660	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.249	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353289/suppl/GSM2353289_A52084400939114082215421026196617.CEL.gz	0	Reanalyzed by: GSM2352447		GSM2353289	GSM2353290_A52084400939113082215421026196558.CEL	"SUBJ.0660, SLE, week16"	GSM2353290	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.9699453551912	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0660	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.249	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353290/suppl/GSM2353290_A52084400939113082215421026196558.CEL.gz	0			GSM2353290	GSM2353291_A52084400939115082215421026196673.CEL	"SUBJ.0660, SLE, week52"	GSM2353291	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.9699453551912	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0660	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.249	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353291/suppl/GSM2353291_A52084400939115082215421026196673.CEL.gz	0			GSM2353291	GSM2353292_A52084400939497101415421438761041.CEL	"SUBJ.0056, SLE, baseline"	GSM2353292	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.1616438356164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0056	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 97	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353292/suppl/GSM2353292_A52084400939497101415421438761041.CEL.gz	0	Reanalyzed by: GSM2351619		GSM2353292	GSM2353293_A52084400940651100115421364640619.CEL	"SUBJ.0056, SLE, week16"	GSM2353293	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.1616438356164	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0056	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 97	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353293/suppl/GSM2353293_A52084400940651100115421364640619.CEL.gz	0			GSM2353293	GSM2353294_A52084400940656100115421372840763.CEL	"SUBJ.0056, SLE, week52"	GSM2353294	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.1616438356164	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0056	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 97	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353294/suppl/GSM2353294_A52084400940656100115421372840763.CEL.gz	0			GSM2353294	GSM2353295_A52084400939116082215421026196761.CEL	"SUBJ.0528, SLE, baseline"	GSM2353295	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.7232876712328	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0528	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.84	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353295/suppl/GSM2353295_A52084400939116082215421026196761.CEL.gz	0	Reanalyzed by: GSM2351621		GSM2353295	GSM2353296_A52084400939115082215421026196705.CEL	"SUBJ.0528, SLE, week16"	GSM2353296	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.7232876712328	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0528	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.84	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353296/suppl/GSM2353296_A52084400939115082215421026196705.CEL.gz	0			GSM2353296	GSM2353297_A52084400939116082215421026196727.CEL	"SUBJ.0528, SLE, week52"	GSM2353297	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.7232876712328	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0528	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.84	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353297/suppl/GSM2353297_A52084400939116082215421026196727.CEL.gz	0			GSM2353297	GSM2353298_A52084400939234091415421177246950.CEL	"SUBJ.1522, SLE, baseline"	GSM2353298	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.775956284153	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1522	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.05	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.171	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353298/suppl/GSM2353298_A52084400939234091415421177246950.CEL.gz	0	Reanalyzed by: GSM2351037		GSM2353298	GSM2353299_A52084400939233091415421177246891.CEL	"SUBJ.1522, SLE, week16"	GSM2353299	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.775956284153	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1522	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.05	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.171	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353299/suppl/GSM2353299_A52084400939233091415421177246891.CEL.gz	0			GSM2353299	GSM2353300_A52084400939233091415421177246911.CEL	"SUBJ.1522, SLE, week52"	GSM2353300	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 35.775956284153	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1522	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.05	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.171	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353300/suppl/GSM2353300_A52084400939233091415421177246911.CEL.gz	0			GSM2353300	GSM2353301_A52084400939113082215421026196569.CEL	"SUBJ.0233, SLE, baseline"	GSM2353301	sledai_at_baseline: 23	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.8164383561643	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0233	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.478	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353301/suppl/GSM2353301_A52084400939113082215421026196569.CEL.gz	0	Reanalyzed by: GSM2351986		GSM2353301	GSM2353302_A52084400939115082215421026196677.CEL	"SUBJ.0233, SLE, week16"	GSM2353302	sledai_at_baseline: 23	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.8164383561643	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0233	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.478	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353302/suppl/GSM2353302_A52084400939115082215421026196677.CEL.gz	0			GSM2353302	GSM2353303_A52084400939908082115420971516338.CEL	"SUBJ.0233, SLE, week52"	GSM2353303	sledai_at_baseline: 23	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.8164383561643	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0233	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.478	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353303/suppl/GSM2353303_A52084400939908082115420971516338.CEL.gz	0			GSM2353303	GSM2353304_A52084400940659100115421372840937.CEL	"SUBJ.0942, SLE, baseline"	GSM2353304	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.1698630136986	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0942	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.75	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.341	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353304/suppl/GSM2353304_A52084400940659100115421372840937.CEL.gz	0	Reanalyzed by: GSM2351149		GSM2353304	GSM2353305_A52084400940657100115421372840840.CEL	"SUBJ.0942, SLE, week16"	GSM2353305	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.1698630136986	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0942	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.75	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.341	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353305/suppl/GSM2353305_A52084400940657100115421372840840.CEL.gz	0			GSM2353305	GSM2353306_A52084400940658100115421372840903.CEL	"SUBJ.0942, SLE, week52"	GSM2353306	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.1698630136986	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0942	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.75	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.341	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353306/suppl/GSM2353306_A52084400940658100115421372840903.CEL.gz	0			GSM2353306	GSM2353307_A52084400940068100715421373649300.CEL	"SUBJ.1081, SLE, baseline"	GSM2353307	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 69.4575342465753	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1081	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.158	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353307/suppl/GSM2353307_A52084400940068100715421373649300.CEL.gz	0	Reanalyzed by: GSM2350958		GSM2353307	GSM2353308_A52084400940067100715421373649219.CEL	"SUBJ.1081, SLE, week16"	GSM2353308	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 69.4575342465753	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1081	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.158	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353308/suppl/GSM2353308_A52084400940067100715421373649219.CEL.gz	0			GSM2353308	GSM2353309_A52084400940081100815421437950409.CEL	"SUBJ.1081, SLE, week52"	GSM2353309	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 69.4575342465753	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1081	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.158	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353309/suppl/GSM2353309_A52084400940081100815421437950409.CEL.gz	0			GSM2353309	GSM2353310_A52084400939230091315421177046053.CEL	"SUBJ.1565, SLE, baseline"	GSM2353310	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.8054794520548	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1565	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 25	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.943	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.214	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353310/suppl/GSM2353310_A52084400939230091315421177046053.CEL.gz	0	Reanalyzed by: GSM2351163		GSM2353310	GSM2353311_A52084400939231091315421177046175.CEL	"SUBJ.1565, SLE, week16"	GSM2353311	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.8054794520548	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1565	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 25	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.943	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.214	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353311/suppl/GSM2353311_A52084400939231091315421177046175.CEL.gz	0			GSM2353311	GSM2353312_A52084400939230091315421177046055.CEL	"SUBJ.1565, SLE, week52"	GSM2353312	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.8054794520548	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1565	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 25	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.943	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.214	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353312/suppl/GSM2353312_A52084400939230091315421177046055.CEL.gz	0			GSM2353312	GSM2353313_A52084400940545091515421247226815.CEL	"SUBJ.1278, SLE, baseline"	GSM2353313	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9125683060109	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1278	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.707	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.135	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353313/suppl/GSM2353313_A52084400940545091515421247226815.CEL.gz	0	Reanalyzed by: GSM2351980		GSM2353313	GSM2353314_A52084400940545091515421247226807.CEL	"SUBJ.1278, SLE, week16"	GSM2353314	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9125683060109	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1278	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.707	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.135	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353314/suppl/GSM2353314_A52084400940545091515421247226807.CEL.gz	0			GSM2353314	GSM2353315_A52084400940545091515421247226793.CEL	"SUBJ.1278, SLE, week52"	GSM2353315	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9125683060109	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1278	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.707	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.135	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353315/suppl/GSM2353315_A52084400940545091515421247226793.CEL.gz	0			GSM2353315	GSM2353316_A52084400939272081315420891403959.CEL	"SUBJ.1274, SLE, baseline"	GSM2353316	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.8602739726027	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1274	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.224	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353316/suppl/GSM2353316_A52084400939272081315420891403959.CEL.gz	0	Reanalyzed by: GSM2351508		GSM2353316	GSM2353317_A52084400939213081815420934611030.CEL	"SUBJ.1274, SLE, week16"	GSM2353317	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.8602739726027	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1274	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.224	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353317/suppl/GSM2353317_A52084400939213081815420934611030.CEL.gz	0			GSM2353317	GSM2353318_A52084400939270081315420891403819.CEL	"SUBJ.1274, SLE, week52"	GSM2353318	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.8602739726027	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1274	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.224	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353318/suppl/GSM2353318_A52084400939270081315420891403819.CEL.gz	0			GSM2353318	GSM2353319_A52084400939920091515421247126530.CEL	"SUBJ.1598, SLE, baseline"	GSM2353319	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.9205479452054	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1598	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.066	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353319/suppl/GSM2353319_A52084400939920091515421247126530.CEL.gz	0	Reanalyzed by: GSM2351461		GSM2353319	GSM2353320_A52084400939921091515421247126596.CEL	"SUBJ.1598, SLE, week16"	GSM2353320	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.9205479452054	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1598	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.066	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353320/suppl/GSM2353320_A52084400939921091515421247126596.CEL.gz	0			GSM2353320	GSM2353321_A52084400939920091515421247126491.CEL	"SUBJ.1598, SLE, week52"	GSM2353321	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.9205479452054	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1598	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.066	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353321/suppl/GSM2353321_A52084400939920091515421247126491.CEL.gz	0			GSM2353321	GSM2353322_A52084400939235091415421177247092.CEL	"SUBJ.1762, SLE, baseline"	GSM2353322	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 61.8383561643835	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1762	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 69	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.295	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353322/suppl/GSM2353322_A52084400939235091415421177247092.CEL.gz	0	Reanalyzed by: GSM2352455		GSM2353322	GSM2353323_A52084400939235091415421177247099.CEL	"SUBJ.1762, SLE, week16"	GSM2353323	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 61.8383561643835	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1762	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 69	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.295	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353323/suppl/GSM2353323_A52084400939235091415421177247099.CEL.gz	0			GSM2353323	GSM2353324_A52084400939234091415421177246951.CEL	"SUBJ.1762, SLE, week52"	GSM2353324	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 61.8383561643835	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1762	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 69	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.295	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353324/suppl/GSM2353324_A52084400939234091415421177246951.CEL.gz	0			GSM2353324	GSM2353325_A52084400939234091415421177246949.CEL	"SUBJ.0582, SLE, week16"	GSM2353325	sledai_at_baseline: 15	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.9071038251366	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0582	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.558	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.06	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353325/suppl/GSM2353325_A52084400939234091415421177246949.CEL.gz	0			GSM2353325	GSM2353326_A52084400940549091515421247348569.CEL	"SUBJ.0582, SLE, week52"	GSM2353326	sledai_at_baseline: 15	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.9071038251366	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0582	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.558	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.06	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353326/suppl/GSM2353326_A52084400940549091515421247348569.CEL.gz	0			GSM2353326	GSM2353327_A52084400939847091515421247126707.CEL	"SUBJ.0482, SLE, baseline"	GSM2353327	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.0164383561643	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0482	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 127	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.851	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.227	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353327/suppl/GSM2353327_A52084400939847091515421247126707.CEL.gz	0	Reanalyzed by: GSM2351571		GSM2353327	GSM2353328_A52084400939847091515421247126694.CEL	"SUBJ.0482, SLE, week16"	GSM2353328	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.0164383561643	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0482	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 127	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.851	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.227	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353328/suppl/GSM2353328_A52084400939847091515421247126694.CEL.gz	0			GSM2353328	GSM2353329_A52084400939847091515421247126711.CEL	"SUBJ.0482, SLE, week52"	GSM2353329	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.0164383561643	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0482	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 127	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.851	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.227	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353329/suppl/GSM2353329_A52084400939847091515421247126711.CEL.gz	0			GSM2353329	GSM2353330_A52084400939852091415421246947147.CEL	"SUBJ.0948, SLE, baseline"	GSM2353330	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.517808219178	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0948	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.242	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353330/suppl/GSM2353330_A52084400939852091415421246947147.CEL.gz	0	Reanalyzed by: GSM2352184		GSM2353330	GSM2353331_A52084400939854091415421246947288.CEL	"SUBJ.0948, SLE, week52"	GSM2353331	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 49.517808219178	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0948	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.242	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353331/suppl/GSM2353331_A52084400939854091415421246947288.CEL.gz	0			GSM2353331	GSM2353332_A52084400939271081315420891403914.CEL	"SUBJ.1513, SLE, baseline"	GSM2353332	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.9780821917808	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1513	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.239	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353332/suppl/GSM2353332_A52084400939271081315420891403914.CEL.gz	0	Reanalyzed by: GSM2351637		GSM2353332	GSM2353333_A52084400939213081815420934611011.CEL	"SUBJ.1513, SLE, week16"	GSM2353333	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.9780821917808	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1513	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.239	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353333/suppl/GSM2353333_A52084400939213081815420934611011.CEL.gz	0			GSM2353333	GSM2353334_A52084400939212081815420934610950.CEL	"SUBJ.1513, SLE, week52"	GSM2353334	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.9780821917808	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1513	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.45	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.239	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353334/suppl/GSM2353334_A52084400939212081815420934610950.CEL.gz	0			GSM2353334	GSM2353335_A52084400939116082215421026196733.CEL	"SUBJ.0598, SLE, baseline"	GSM2353335	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.8306010928961	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0598	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.44	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.28	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353335/suppl/GSM2353335_A52084400939116082215421026196733.CEL.gz	0	Reanalyzed by: GSM2352015		GSM2353335	GSM2353336_A52084400939114082215421026196611.CEL	"SUBJ.0598, SLE, week16"	GSM2353336	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.8306010928961	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0598	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.44	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.28	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353336/suppl/GSM2353336_A52084400939114082215421026196611.CEL.gz	0			GSM2353336	GSM2353337_A52084400939114082215421026196607.CEL	"SUBJ.0598, SLE, week52"	GSM2353337	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.8306010928961	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0598	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.44	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.28	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353337/suppl/GSM2353337_A52084400939114082215421026196607.CEL.gz	0			GSM2353337	GSM2353338_A52084400939846091515421247126612.CEL	"SUBJ.1138, SLE, baseline"	GSM2353338	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.2301369863013	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1138	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 2.29	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.519	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353338/suppl/GSM2353338_A52084400939846091515421247126612.CEL.gz	0	Reanalyzed by: GSM2352207		GSM2353338	GSM2353339_A52084400940545091515421247226828.CEL	"SUBJ.1138, SLE, week16"	GSM2353339	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.2301369863013	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1138	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 2.29	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.519	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353339/suppl/GSM2353339_A52084400940545091515421247226828.CEL.gz	0			GSM2353339	GSM2353340_A52084400940546091515421247226878.CEL	"SUBJ.1138, SLE, week52"	GSM2353340	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.2301369863013	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1138	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): H	c3_at_baseline (g/l): 2.29	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.519	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353340/suppl/GSM2353340_A52084400940546091515421247226878.CEL.gz	0			GSM2353340	GSM2353341_A52084400940550091515421247348629.CEL	"SUBJ.0390, SLE, baseline"	GSM2353341	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 56.1479452054794	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0390	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.264	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353341/suppl/GSM2353341_A52084400940550091515421247348629.CEL.gz	0	Reanalyzed by: GSM2351240		GSM2353341	GSM2353342_A52084400940551091515421247348653.CEL	"SUBJ.0390, SLE, week16"	GSM2353342	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 56.1479452054794	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0390	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.264	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353342/suppl/GSM2353342_A52084400940551091515421247348653.CEL.gz	0			GSM2353342	GSM2353343_A52084400940549091515421247348576.CEL	"SUBJ.0390, SLE, week52"	GSM2353343	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 56.1479452054794	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0390	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.264	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353343/suppl/GSM2353343_A52084400940549091515421247348576.CEL.gz	0			GSM2353343	GSM2353344_A52084400939920091515421247126523.CEL	"SUBJ.0607, SLE, baseline"	GSM2353344	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.7540983606557	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0607	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.957	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.184	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353344/suppl/GSM2353344_A52084400939920091515421247126523.CEL.gz	0	Reanalyzed by: GSM2352574		GSM2353344	GSM2353345_A52084400939921091515421247126559.CEL	"SUBJ.0607, SLE, week16"	GSM2353345	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.7540983606557	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0607	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.957	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.184	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353345/suppl/GSM2353345_A52084400939921091515421247126559.CEL.gz	0			GSM2353345	GSM2353346_A52084400939846091515421247126655.CEL	"SUBJ.0607, SLE, week52"	GSM2353346	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.7540983606557	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0607	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.957	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.184	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353346/suppl/GSM2353346_A52084400939846091515421247126655.CEL.gz	0			GSM2353346	GSM2353347_A52084400939116082215421026196760.CEL	"SUBJ.0259, SLE, baseline"	GSM2353347	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.7540983606557	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0259	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 54	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.886	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.114	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353347/suppl/GSM2353347_A52084400939116082215421026196760.CEL.gz	0	Reanalyzed by: GSM2351449		GSM2353347	GSM2353348_A52084400939496101415421438760412.CEL	"SUBJ.0259, SLE, week16"	GSM2353348	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.7540983606557	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0259	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 54	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.886	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.114	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353348/suppl/GSM2353348_A52084400939496101415421438760412.CEL.gz	0			GSM2353348	GSM2353349_A52084400939113082215421026196546.CEL	"SUBJ.1271, SLE, baseline"	GSM2353349	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.0383561643835	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1271	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 117	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.291	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353349/suppl/GSM2353349_A52084400939113082215421026196546.CEL.gz	0	Reanalyzed by: GSM2350951		GSM2353349	GSM2353350_A52084400939114082215421026196604.CEL	"SUBJ.1271, SLE, week16"	GSM2353350	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.0383561643835	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1271	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 117	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.291	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353350/suppl/GSM2353350_A52084400939114082215421026196604.CEL.gz	0			GSM2353350	GSM2353351_A52084400939115082215421026196669.CEL	"SUBJ.1271, SLE, week52"	GSM2353351	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 45.0383561643835	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1271	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 117	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.15	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.291	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353351/suppl/GSM2353351_A52084400939115082215421026196669.CEL.gz	0			GSM2353351	GSM2353352_A52084400939497101415421438761049.CEL	"SUBJ.1602, SLE, baseline"	GSM2353352	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 60.2986301369863	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1602	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.25	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353352/suppl/GSM2353352_A52084400939497101415421438761049.CEL.gz	0	Reanalyzed by: GSM2350991		GSM2353352	GSM2353353_A52084400939233091415421177246930.CEL	"SUBJ.1602, SLE, week16"	GSM2353353	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 60.2986301369863	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1602	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.25	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353353/suppl/GSM2353353_A52084400939233091415421177246930.CEL.gz	0			GSM2353353	GSM2353354_A52084400940545091515421247226814.CEL	"SUBJ.1602, SLE, week52"	GSM2353354	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 60.2986301369863	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1602	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.25	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353354/suppl/GSM2353354_A52084400940545091515421247226814.CEL.gz	0			GSM2353354	GSM2353355_A52084400939213081815420934611041.CEL	"SUBJ.1259, SLE, baseline"	GSM2353355	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.9754098360655	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1259	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.957	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.191	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353355/suppl/GSM2353355_A52084400939213081815420934611041.CEL.gz	0	Reanalyzed by: GSM2351900		GSM2353355	GSM2353356_A52084400939272081315420891403938.CEL	"SUBJ.1259, SLE, week16"	GSM2353356	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.9754098360655	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1259	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.957	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.191	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353356/suppl/GSM2353356_A52084400939272081315420891403938.CEL.gz	0			GSM2353356	GSM2353357_A52084400939272081315420891403962.CEL	"SUBJ.1259, SLE, week52"	GSM2353357	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.9754098360655	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1259	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.957	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.191	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353357/suppl/GSM2353357_A52084400939272081315420891403962.CEL.gz	0			GSM2353357	GSM2353358_A52084400939854091415421246947246.CEL	"SUBJ.0629, SLE, baseline"	GSM2353358	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.931506849315	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0629	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 16	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.478	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353358/suppl/GSM2353358_A52084400939854091415421246947246.CEL.gz	0	Reanalyzed by: GSM2352514		GSM2353358	GSM2353359_A52084400939855091415421246947306.CEL	"SUBJ.0629, SLE, week16"	GSM2353359	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.931506849315	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0629	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 16	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.478	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353359/suppl/GSM2353359_A52084400939855091415421246947306.CEL.gz	0			GSM2353359	GSM2353360_A52084400939855091415421246947339.CEL	"SUBJ.0629, SLE, week52"	GSM2353360	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.931506849315	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0629	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 16	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.478	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353360/suppl/GSM2353360_A52084400939855091415421246947339.CEL.gz	0			GSM2353360	GSM2353361_A52084400939114082215421026196643.CEL	"SUBJ.1006, SLE, baseline"	GSM2353361	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.879781420765	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1006	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.47	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.288	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353361/suppl/GSM2353361_A52084400939114082215421026196643.CEL.gz	0	Reanalyzed by: GSM2352467		GSM2353361	GSM2353362_A52084400939115082215421026196697.CEL	"SUBJ.1006, SLE, week16"	GSM2353362	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.879781420765	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1006	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.47	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.288	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353362/suppl/GSM2353362_A52084400939115082215421026196697.CEL.gz	0			GSM2353362	GSM2353363_A52084400939113082215421026196589.CEL	"SUBJ.1006, SLE, week52"	GSM2353363	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.879781420765	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1006	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.47	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.288	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353363/suppl/GSM2353363_A52084400939113082215421026196589.CEL.gz	0			GSM2353363	GSM2353364_A52084400939920091515421247126505.CEL	"SUBJ.0198, SLE, baseline"	GSM2353364	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.9013698630137	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0198	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.998	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.181	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353364/suppl/GSM2353364_A52084400939920091515421247126505.CEL.gz	0	Reanalyzed by: GSM2351073		GSM2353364	GSM2353365_A52084400939921091515421247126568.CEL	"SUBJ.0198, SLE, week16"	GSM2353365	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.9013698630137	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0198	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.998	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.181	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353365/suppl/GSM2353365_A52084400939921091515421247126568.CEL.gz	0			GSM2353365	GSM2353366_A52084400939846091515421247126656.CEL	"SUBJ.0198, SLE, week52"	GSM2353366	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.9013698630137	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0198	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.998	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.181	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353366/suppl/GSM2353366_A52084400939846091515421247126656.CEL.gz	0			GSM2353366	GSM2353367_A52084400940658100115421372840871.CEL	"SUBJ.0028, SLE, baseline"	GSM2353367	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.6830601092896	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0028	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 53	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.305	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353367/suppl/GSM2353367_A52084400940658100115421372840871.CEL.gz	0	Reanalyzed by: GSM2351187		GSM2353367	GSM2353368_A52084400940659100115421372840979.CEL	"SUBJ.0028, SLE, week16"	GSM2353368	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.6830601092896	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0028	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 53	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.305	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353368/suppl/GSM2353368_A52084400940659100115421372840979.CEL.gz	0			GSM2353368	GSM2353369_A52084400940657100115421372840859.CEL	"SUBJ.0028, SLE, week52"	GSM2353369	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.6830601092896	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0028	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 53	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.305	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353369/suppl/GSM2353369_A52084400940657100115421372840859.CEL.gz	0			GSM2353369	GSM2353370_A52084400939233091415421177246904.CEL	"SUBJ.1724, SLE, baseline"	GSM2353370	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8383561643835	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1724	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 52	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.44	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.278	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353370/suppl/GSM2353370_A52084400939233091415421177246904.CEL.gz	0	Reanalyzed by: GSM2351358		GSM2353370	GSM2353371_A52084400939853091415421246947192.CEL	"SUBJ.1724, SLE, week16"	GSM2353371	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8383561643835	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1724	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 52	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.44	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.278	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353371/suppl/GSM2353371_A52084400939853091415421246947192.CEL.gz	0			GSM2353371	GSM2353372_A52084400939235091415421177247091.CEL	"SUBJ.1724, SLE, week52"	GSM2353372	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8383561643835	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1724	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 52	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.44	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.278	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353372/suppl/GSM2353372_A52084400939235091415421177247091.CEL.gz	0			GSM2353372	GSM2353373_A52084400940545091515421247226831.CEL	"SUBJ.0743, SLE, baseline"	GSM2353373	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.8497267759562	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0743	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 96	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.149	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353373/suppl/GSM2353373_A52084400940545091515421247226831.CEL.gz	0	Reanalyzed by: GSM2352631		GSM2353373	GSM2353374_A52084400940545091515421247226829.CEL	"SUBJ.0743, SLE, week16"	GSM2353374	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.8497267759562	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0743	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 96	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.149	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353374/suppl/GSM2353374_A52084400940545091515421247226829.CEL.gz	0			GSM2353374	GSM2353375_A52084400940544091515421247226732.CEL	"SUBJ.0743, SLE, week52"	GSM2353375	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.8497267759562	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0743	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 96	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.149	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353375/suppl/GSM2353375_A52084400940544091515421247226732.CEL.gz	0			GSM2353375	GSM2353376_A52084400940068100715421373649297.CEL	"SUBJ.1083, SLE, baseline"	GSM2353376	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.7978142076502	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1083	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.74	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.155	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353376/suppl/GSM2353376_A52084400940068100715421373649297.CEL.gz	0	Reanalyzed by: GSM2351699		GSM2353376	GSM2353377_A52084400940069100715421373649345.CEL	"SUBJ.1083, SLE, week16"	GSM2353377	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.7978142076502	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1083	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.74	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.155	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353377/suppl/GSM2353377_A52084400940069100715421373649345.CEL.gz	0			GSM2353377	GSM2353378_A52084400940067100715421373649255.CEL	"SUBJ.1083, SLE, week52"	GSM2353378	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.7978142076502	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1083	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.74	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.155	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353378/suppl/GSM2353378_A52084400940067100715421373649255.CEL.gz	0			GSM2353378	GSM2353379_A52084400940546091515421247226875.CEL	"SUBJ.0839, SLE, baseline"	GSM2353379	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.9945205479452	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0839	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 192	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.461	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.072	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353379/suppl/GSM2353379_A52084400940546091515421247226875.CEL.gz	0	Reanalyzed by: GSM2352632		GSM2353379	GSM2353380_A52084400940546091515421247226859.CEL	"SUBJ.0839, SLE, week16"	GSM2353380	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.9945205479452	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0839	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 192	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.461	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.072	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353380/suppl/GSM2353380_A52084400940546091515421247226859.CEL.gz	0			GSM2353380	GSM2353381_A52084400940544091515421247226729.CEL	"SUBJ.0839, SLE, week52"	GSM2353381	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.9945205479452	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0839	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 192	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.461	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.072	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353381/suppl/GSM2353381_A52084400940544091515421247226729.CEL.gz	0			GSM2353381	GSM2353382_A52084400939853091415421246947226.CEL	"SUBJ.0742, SLE, baseline"	GSM2353382	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8767123287671	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0742	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.858	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.15	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353382/suppl/GSM2353382_A52084400939853091415421246947226.CEL.gz	0	Reanalyzed by: GSM2351126		GSM2353382	GSM2353383_A52084400939234091415421177246958.CEL	"SUBJ.0742, SLE, week16"	GSM2353383	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8767123287671	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0742	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.858	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.15	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353383/suppl/GSM2353383_A52084400939234091415421177246958.CEL.gz	0			GSM2353383	GSM2353384_A52084400939843091415421247047442.CEL	"SUBJ.0742, SLE, week52"	GSM2353384	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8767123287671	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0742	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 8	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.858	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.15	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353384/suppl/GSM2353384_A52084400939843091415421247047442.CEL.gz	0			GSM2353384	GSM2353385_A52084400939213081815420934611008.CEL	"SUBJ.1784, SLE, baseline"	GSM2353385	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.7972602739726	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1784	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.46	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.311	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353385/suppl/GSM2353385_A52084400939213081815420934611008.CEL.gz	0	Reanalyzed by: GSM2351552		GSM2353385	GSM2353386_A52084400939269081315420891403759.CEL	"SUBJ.1784, SLE, week16"	GSM2353386	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.7972602739726	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1784	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.46	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.311	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353386/suppl/GSM2353386_A52084400939269081315420891403759.CEL.gz	0			GSM2353386	GSM2353387_A52084400939269081315420891403785.CEL	"SUBJ.1784, SLE, week52"	GSM2353387	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.7972602739726	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1784	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.46	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.311	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353387/suppl/GSM2353387_A52084400939269081315420891403785.CEL.gz	0			GSM2353387	GSM2353388_A52084400940657100115421372840860.CEL	"SUBJ.0117, SLE, baseline"	GSM2353388	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.7808219178082	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0117	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.862	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.071	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353388/suppl/GSM2353388_A52084400940657100115421372840860.CEL.gz	0	Reanalyzed by: GSM2351754		GSM2353388	GSM2353389_A52084400940659100115421372840946.CEL	"SUBJ.0117, SLE, week16"	GSM2353389	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.7808219178082	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0117	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.862	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.071	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353389/suppl/GSM2353389_A52084400940659100115421372840946.CEL.gz	0			GSM2353389	GSM2353390_A52084400940658100115421372840870.CEL	"SUBJ.0117, SLE, week52"	GSM2353390	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.7808219178082	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0117	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 57	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.862	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.071	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353390/suppl/GSM2353390_A52084400940658100115421372840870.CEL.gz	0			GSM2353390	GSM2353391_A52084400940068100715421373649280.CEL	"SUBJ.1369, SLE, baseline"	GSM2353391	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.5150684931507	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1369	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.5	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.255	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353391/suppl/GSM2353391_A52084400940068100715421373649280.CEL.gz	0	Reanalyzed by: GSM2350977		GSM2353391	GSM2353392_A52084400940068100715421373649290.CEL	"SUBJ.1369, SLE, week16"	GSM2353392	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.5150684931507	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1369	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.5	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.255	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353392/suppl/GSM2353392_A52084400940068100715421373649290.CEL.gz	0			GSM2353392	GSM2353393_A52084400940068100715421373649304.CEL	"SUBJ.1369, SLE, week52"	GSM2353393	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.5150684931507	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1369	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.5	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.255	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353393/suppl/GSM2353393_A52084400940068100715421373649304.CEL.gz	0			GSM2353393	GSM2353394_A52084400939852091415421246947130.CEL	"SUBJ.1449, SLE, baseline"	GSM2353394	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.811475409836	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1449	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.095	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353394/suppl/GSM2353394_A52084400939852091415421246947130.CEL.gz	0	Reanalyzed by: GSM2351752		GSM2353394	GSM2353395_A52084400939852091415421246947128.CEL	"SUBJ.1449, SLE, week16"	GSM2353395	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.811475409836	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1449	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.095	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353395/suppl/GSM2353395_A52084400939852091415421246947128.CEL.gz	0			GSM2353395	GSM2353396_A52084400939855091415421246947344.CEL	"SUBJ.1449, SLE, week52"	GSM2353396	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 28.811475409836	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1449	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.095	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353396/suppl/GSM2353396_A52084400939855091415421246947344.CEL.gz	0			GSM2353396	GSM2353397_A52084400940659100115421372840942.CEL	"SUBJ.0930, SLE, baseline"	GSM2353397	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8551912568306	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0930	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 70	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.98	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.192	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353397/suppl/GSM2353397_A52084400940659100115421372840942.CEL.gz	0	Reanalyzed by: GSM2351122		GSM2353397	GSM2353398_A52084400939847091515421247126683.CEL	"SUBJ.0930, SLE, week16"	GSM2353398	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8551912568306	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0930	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 70	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.98	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.192	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353398/suppl/GSM2353398_A52084400939847091515421247126683.CEL.gz	0			GSM2353398	GSM2353399_A52084400940651100115421364640581.CEL	"SUBJ.0930, SLE, week52"	GSM2353399	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8551912568306	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0930	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 70	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.98	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.192	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353399/suppl/GSM2353399_A52084400940651100115421364640581.CEL.gz	0			GSM2353399	GSM2353400_A52084400940548091515421247226928.CEL	"SUBJ.1391, SLE, baseline"	GSM2353400	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.9808219178082	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1391	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 31	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.811	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.068	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353400/suppl/GSM2353400_A52084400940548091515421247226928.CEL.gz	0	Reanalyzed by: GSM2350996		GSM2353400	GSM2353401_A52084400940548091515421247226941.CEL	"SUBJ.1391, SLE, week16"	GSM2353401	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.9808219178082	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1391	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 31	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.811	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.068	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353401/suppl/GSM2353401_A52084400940548091515421247226941.CEL.gz	0			GSM2353401	GSM2353402_A52084400940546091515421247226881.CEL	"SUBJ.1391, SLE, week52"	GSM2353402	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 59.9808219178082	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1391	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 31	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.811	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.068	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353402/suppl/GSM2353402_A52084400940546091515421247226881.CEL.gz	0			GSM2353402	GSM2353403_A52084400939845091415421247047584.CEL	"SUBJ.0626, SLE, baseline"	GSM2353403	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.3808219178082	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0626	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 48	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.343	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353403/suppl/GSM2353403_A52084400939845091415421247047584.CEL.gz	0	Reanalyzed by: GSM2351424		GSM2353403	GSM2353404_A52084400939228091315421177045868.CEL	"SUBJ.0626, SLE, week16"	GSM2353404	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.3808219178082	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0626	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 48	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.343	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353404/suppl/GSM2353404_A52084400939228091315421177045868.CEL.gz	0			GSM2353404	GSM2353405_A52084400939230091315421177046043.CEL	"SUBJ.0626, SLE, week52"	GSM2353405	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.3808219178082	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0626	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 48	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.22	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.343	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353405/suppl/GSM2353405_A52084400939230091315421177046043.CEL.gz	0			GSM2353405	GSM2353406_A52084400940544091515421247226775.CEL	"SUBJ.1603, SLE, baseline"	GSM2353406	sledai_at_baseline: 19	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.1287671232876	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1603	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.782	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.087	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353406/suppl/GSM2353406_A52084400940544091515421247226775.CEL.gz	0	Reanalyzed by: GSM2352225		GSM2353406	GSM2353407_A52084400940548091515421247226953.CEL	"SUBJ.1603, SLE, week16"	GSM2353407	sledai_at_baseline: 19	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.1287671232876	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1603	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.782	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.087	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353407/suppl/GSM2353407_A52084400940548091515421247226953.CEL.gz	0			GSM2353407	GSM2353408_A52084400940551091515421247348671.CEL	"SUBJ.1603, SLE, week52"	GSM2353408	sledai_at_baseline: 19	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.1287671232876	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1603	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 18	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.782	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.087	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353408/suppl/GSM2353408_A52084400940551091515421247348671.CEL.gz	0			GSM2353408	GSM2353409_A52084400939232091415421177246825.CEL	"SUBJ.0619, SLE, baseline"	GSM2353409	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 18.4109589041095	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0619	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 90	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353409/suppl/GSM2353409_A52084400939232091415421177246825.CEL.gz	0	Reanalyzed by: GSM2351751		GSM2353409	GSM2353410_A52084400939853091415421246947202.CEL	"SUBJ.0619, SLE, week16"	GSM2353410	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 18.4109589041095	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0619	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 90	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353410/suppl/GSM2353410_A52084400939853091415421246947202.CEL.gz	0			GSM2353410	GSM2353411_A52084400939853091415421246947208.CEL	"SUBJ.0619, SLE, week52"	GSM2353411	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 18.4109589041095	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0619	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 90	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353411/suppl/GSM2353411_A52084400939853091415421246947208.CEL.gz	0			GSM2353411	GSM2353412_A52084400939854091415421246947290.CEL	"SUBJ.0666, SLE, baseline"	GSM2353412	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.8142076502732	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0666	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.664	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.124	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353412/suppl/GSM2353412_A52084400939854091415421246947290.CEL.gz	0	Reanalyzed by: GSM2352221		GSM2353412	GSM2353413_A52084400939855091415421246947318.CEL	"SUBJ.0666, SLE, week16"	GSM2353413	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.8142076502732	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0666	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.664	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.124	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353413/suppl/GSM2353413_A52084400939855091415421246947318.CEL.gz	0			GSM2353413	GSM2353414_A52084400939852091415421246947169.CEL	"SUBJ.0666, SLE, week52"	GSM2353414	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.8142076502732	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0666	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.664	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.124	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353414/suppl/GSM2353414_A52084400939852091415421246947169.CEL.gz	0			GSM2353414	GSM2353415_A52084400939845091415421247047561.CEL	"SUBJ.1710, SLE, baseline"	GSM2353415	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.0767123287671	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1710	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.7	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.405	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353415/suppl/GSM2353415_A52084400939845091415421247047561.CEL.gz	0	Reanalyzed by: GSM2350986		GSM2353415	GSM2353416_A52084400939853091415421246947228.CEL	"SUBJ.1710, SLE, week16"	GSM2353416	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.0767123287671	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1710	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.7	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.405	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353416/suppl/GSM2353416_A52084400939853091415421246947228.CEL.gz	0			GSM2353416	GSM2353417_A52084400939853091415421246947212.CEL	"SUBJ.1710, SLE, week52"	GSM2353417	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.0767123287671	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1710	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.7	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): H	c4_at_baseline (g/l): 0.405	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353417/suppl/GSM2353417_A52084400939853091415421246947212.CEL.gz	0			GSM2353417	GSM2353418_A52084400939855091415421246947336.CEL	"SUBJ.0986, SLE, baseline"	GSM2353418	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.7404371584699	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0986	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.294	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353418/suppl/GSM2353418_A52084400939855091415421246947336.CEL.gz	0	Reanalyzed by: GSM2350959		GSM2353418	GSM2353419_A52084400939852091415421246947122.CEL	"SUBJ.0986, SLE, week16"	GSM2353419	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.7404371584699	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0986	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.294	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353419/suppl/GSM2353419_A52084400939852091415421246947122.CEL.gz	0			GSM2353419	GSM2353420_A52084400939855091415421246947327.CEL	"SUBJ.0986, SLE, week52"	GSM2353420	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.7404371584699	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0986	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.294	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353420/suppl/GSM2353420_A52084400939855091415421246947327.CEL.gz	0			GSM2353420	GSM2353421_A52084400939230091315421177046046.CEL	"SUBJ.1122, SLE, baseline"	GSM2353421	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.2602739726027	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1122	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.248	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353421/suppl/GSM2353421_A52084400939230091315421177046046.CEL.gz	0	Reanalyzed by: GSM2352240		GSM2353421	GSM2353422_A52084400939844091415421247047494.CEL	"SUBJ.1122, SLE, week16"	GSM2353422	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.2602739726027	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1122	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.248	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353422/suppl/GSM2353422_A52084400939844091415421247047494.CEL.gz	0			GSM2353422	GSM2353423_A52084400939845091415421247047549.CEL	"SUBJ.1122, SLE, week52"	GSM2353423	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.2602739726027	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1122	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.248	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353423/suppl/GSM2353423_A52084400939845091415421247047549.CEL.gz	0			GSM2353423	GSM2353424_A52084400939844091415421247047519.CEL	"SUBJ.1493, SLE, baseline"	GSM2353424	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8794520547945	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1493	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.141	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353424/suppl/GSM2353424_A52084400939844091415421247047519.CEL.gz	0	Reanalyzed by: GSM2352551		GSM2353424	GSM2353425_A52084400939116082215421026196756.CEL	"SUBJ.1493, SLE, week16"	GSM2353425	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8794520547945	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1493	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.141	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353425/suppl/GSM2353425_A52084400939116082215421026196756.CEL.gz	0			GSM2353425	GSM2353426_A52084400939854091415421246947249.CEL	"SUBJ.1493, SLE, week52"	GSM2353426	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 51.8794520547945	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1493	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 6	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.141	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353426/suppl/GSM2353426_A52084400939854091415421246947249.CEL.gz	0			GSM2353426	GSM2353427_A52084400939231091315421177046202.CEL	"SUBJ.0363, SLE, baseline"	GSM2353427	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.9561643835616	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0363	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.6	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.307	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353427/suppl/GSM2353427_A52084400939231091315421177046202.CEL.gz	0	Reanalyzed by: GSM2351220		GSM2353427	GSM2353428_A52084400939844091415421247047482.CEL	"SUBJ.0363, SLE, week16"	GSM2353428	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.9561643835616	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0363	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.6	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.307	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353428/suppl/GSM2353428_A52084400939844091415421247047482.CEL.gz	0			GSM2353428	GSM2353429_A52084400939230091315421177046082.CEL	"SUBJ.0363, SLE, week52"	GSM2353429	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.9561643835616	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0363	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.6	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.307	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353429/suppl/GSM2353429_A52084400939230091315421177046082.CEL.gz	0			GSM2353429	GSM2353430_A52084400940548091515421247226934.CEL	"SUBJ.0230, SLE, baseline"	GSM2353430	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.4191780821917	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0230	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.998	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.305	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353430/suppl/GSM2353430_A52084400940548091515421247226934.CEL.gz	0	Reanalyzed by: GSM2352162		GSM2353430	GSM2353431_A52084400940548091515421247226918.CEL	"SUBJ.0230, SLE, week16"	GSM2353431	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.4191780821917	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0230	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.998	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.305	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353431/suppl/GSM2353431_A52084400940548091515421247226918.CEL.gz	0			GSM2353431	GSM2353432_A52084400940548091515421247226944.CEL	"SUBJ.0230, SLE, week52"	GSM2353432	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 38.4191780821917	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0230	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.998	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.305	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353432/suppl/GSM2353432_A52084400940548091515421247226944.CEL.gz	0			GSM2353432	GSM2353433_A52084400939114082215421026196623.CEL	"SUBJ.0331, SLE, baseline"	GSM2353433	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.7616438356164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0331	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.906	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.169	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353433/suppl/GSM2353433_A52084400939114082215421026196623.CEL.gz	0	Reanalyzed by: GSM2351263		GSM2353433	GSM2353434_A52084400939113082215421026196567.CEL	"SUBJ.0331, SLE, week16"	GSM2353434	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.7616438356164	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0331	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.906	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.169	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353434/suppl/GSM2353434_A52084400939113082215421026196567.CEL.gz	0			GSM2353434	GSM2353435_A52084400939113082215421026196550.CEL	"SUBJ.0331, SLE, week52"	GSM2353435	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.7616438356164	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0331	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 15	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.906	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.169	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353435/suppl/GSM2353435_A52084400939113082215421026196550.CEL.gz	0			GSM2353435	GSM2353436_A52084400940067100715421373649214.CEL	"SUBJ.0273, SLE, baseline"	GSM2353436	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.9071038251366	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0273	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 162	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.8	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.211	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353436/suppl/GSM2353436_A52084400940067100715421373649214.CEL.gz	0	Reanalyzed by: GSM2352117		GSM2353436	GSM2353437_A52084400940081100815421437950424.CEL	"SUBJ.0273, SLE, week16"	GSM2353437	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.9071038251366	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0273	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 162	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.8	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.211	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353437/suppl/GSM2353437_A52084400940081100815421437950424.CEL.gz	0			GSM2353437	GSM2353438_A52084400940081100815421437950398.CEL	"SUBJ.0273, SLE, week52"	GSM2353438	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.9071038251366	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0273	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 162	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.8	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.211	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353438/suppl/GSM2353438_A52084400940081100815421437950398.CEL.gz	0			GSM2353438	GSM2353439_A52084400939847091515421247126675.CEL	"SUBJ.1573, SLE, baseline"	GSM2353439	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.2	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1573	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 180	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.622	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.134	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353439/suppl/GSM2353439_A52084400939847091515421247126675.CEL.gz	0	Reanalyzed by: GSM2352055		GSM2353439	GSM2353440_A52084400940545091515421247226790.CEL	"SUBJ.1573, SLE, week16"	GSM2353440	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.2	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1573	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 180	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.622	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.134	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353440/suppl/GSM2353440_A52084400940545091515421247226790.CEL.gz	0			GSM2353440	GSM2353441_A52084400940546091515421247226866.CEL	"SUBJ.1573, SLE, week52"	GSM2353441	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.2	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1573	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 180	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.622	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.134	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353441/suppl/GSM2353441_A52084400940546091515421247226866.CEL.gz	0			GSM2353441	GSM2353442_A52084400940657100115421372840816.CEL	"SUBJ.0272, SLE, baseline"	GSM2353442	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.6602739726027	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0272	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.238	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353442/suppl/GSM2353442_A52084400940657100115421372840816.CEL.gz	0	Reanalyzed by: GSM2351111		GSM2353442	GSM2353443_A52084400940656100115421372840780.CEL	"SUBJ.0272, SLE, week16"	GSM2353443	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.6602739726027	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0272	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.238	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353443/suppl/GSM2353443_A52084400940656100115421372840780.CEL.gz	0			GSM2353443	GSM2353444_A52084400940727100515421373263819.CEL	"SUBJ.0272, SLE, week52"	GSM2353444	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 58.6602739726027	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0272	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.11	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.238	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353444/suppl/GSM2353444_A52084400940727100515421373263819.CEL.gz	0			GSM2353444	GSM2353445_A52084400939855091415421246947323.CEL	"SUBJ.0689, SLE, baseline"	GSM2353445	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.5534246575342	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0689	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 199	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.759	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.064	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353445/suppl/GSM2353445_A52084400939855091415421246947323.CEL.gz	0	Reanalyzed by: GSM2351116		GSM2353445	GSM2353446_A52084400939855091415421246947324.CEL	"SUBJ.0689, SLE, week16"	GSM2353446	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.5534246575342	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0689	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 199	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.759	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.064	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353446/suppl/GSM2353446_A52084400939855091415421246947324.CEL.gz	0			GSM2353446	GSM2353447_A52084400939855091415421246947317.CEL	"SUBJ.0689, SLE, week52"	GSM2353447	sledai_at_baseline: 16	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 27.5534246575342	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0689	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 199	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.759	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.064	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353447/suppl/GSM2353447_A52084400939855091415421246947317.CEL.gz	0			GSM2353447	GSM2353448_A52084400939847091515421247126714.CEL	"SUBJ.0703, SLE, baseline"	GSM2353448	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8360655737704	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0703	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 12	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.41	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.283	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353448/suppl/GSM2353448_A52084400939847091515421247126714.CEL.gz	0	Reanalyzed by: GSM2351339		GSM2353448	GSM2353449_A52084400939846091515421247126651.CEL	"SUBJ.0703, SLE, week16"	GSM2353449	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8360655737704	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0703	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 12	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.41	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.283	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353449/suppl/GSM2353449_A52084400939846091515421247126651.CEL.gz	0			GSM2353449	GSM2353450_A52084400940545091515421247226801.CEL	"SUBJ.0703, SLE, week52"	GSM2353450	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8360655737704	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0703	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 12	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.41	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.283	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353450/suppl/GSM2353450_A52084400940545091515421247226801.CEL.gz	0			GSM2353450	GSM2353451_A52084400939234091415421177246959.CEL	"SUBJ.0493, SLE, baseline"	GSM2353451	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.7506849315068	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0493	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.689	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.068	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353451/suppl/GSM2353451_A52084400939234091415421177246959.CEL.gz	0	Reanalyzed by: GSM2351273		GSM2353451	GSM2353452_A52084400939235091415421177247075.CEL	"SUBJ.0493, SLE, week16"	GSM2353452	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.7506849315068	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0493	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.689	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.068	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353452/suppl/GSM2353452_A52084400939235091415421177247075.CEL.gz	0			GSM2353452	GSM2353453_A52084400939233091415421177246889.CEL	"SUBJ.0493, SLE, week52"	GSM2353453	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.7506849315068	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0493	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.689	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.068	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353453/suppl/GSM2353453_A52084400939233091415421177246889.CEL.gz	0			GSM2353453	GSM2353454_A52084400939852091415421246947161.CEL	"SUBJ.0060, SLE, baseline"	GSM2353454	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.6775956284153	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0060	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 23	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.27	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.232	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353454/suppl/GSM2353454_A52084400939852091415421246947161.CEL.gz	0	Reanalyzed by: GSM2351765		GSM2353454	GSM2353455_A52084400939855091415421246947347.CEL	"SUBJ.0060, SLE, week16"	GSM2353455	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.6775956284153	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0060	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 23	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.27	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.232	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353455/suppl/GSM2353455_A52084400939855091415421246947347.CEL.gz	0			GSM2353455	GSM2353456_A52084400939855091415421246947342.CEL	"SUBJ.0060, SLE, week52"	GSM2353456	sledai_at_baseline: 7	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.6775956284153	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0060	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 23	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.27	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.232	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353456/suppl/GSM2353456_A52084400939855091415421246947342.CEL.gz	0			GSM2353456	GSM2353457_A52084400939269081315420891403801.CEL	"SUBJ.0735, SLE, baseline"	GSM2353457	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.8032786885245	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0735	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.807	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.176	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353457/suppl/GSM2353457_A52084400939269081315420891403801.CEL.gz	0	Reanalyzed by: GSM2351036		GSM2353457	GSM2353458_A52084400939271081315420891403894.CEL	"SUBJ.0735, SLE, week16"	GSM2353458	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.8032786885245	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0735	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.807	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.176	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353458/suppl/GSM2353458_A52084400939271081315420891403894.CEL.gz	0			GSM2353458	GSM2353459_A52084400939269081315420891403763.CEL	"SUBJ.0735, SLE, week52"	GSM2353459	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 31.8032786885245	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0735	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.807	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.176	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353459/suppl/GSM2353459_A52084400939269081315420891403763.CEL.gz	0			GSM2353459	GSM2353460_A52084400940651100115421364640604.CEL	"SUBJ.0157, SLE, week16"	GSM2353460	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.8356164383561	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0157	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.207	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353460/suppl/GSM2353460_A52084400940651100115421364640604.CEL.gz	0			GSM2353460	GSM2353461_A52084400940650100115421364640555.CEL	"SUBJ.0157, SLE, week52"	GSM2353461	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.8356164383561	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0157	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.24	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.207	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353461/suppl/GSM2353461_A52084400940650100115421364640555.CEL.gz	0			GSM2353461	GSM2353462_A52084400939214081815420934611104.CEL	"SUBJ.0166, SLE, baseline"	GSM2353462	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.6639344262295	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0166	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 53	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.581	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353462/suppl/GSM2353462_A52084400939214081815420934611104.CEL.gz	0	Reanalyzed by: GSM2351679		GSM2353462	GSM2353463_A52084400939215081815420934611146.CEL	"SUBJ.0166, SLE, week16"	GSM2353463	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.6639344262295	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0166	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 53	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.581	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353463/suppl/GSM2353463_A52084400939215081815420934611146.CEL.gz	0			GSM2353463	GSM2353464_A52084400939213081815420934611018.CEL	"SUBJ.0166, SLE, week52"	GSM2353464	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 23.6639344262295	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0166	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 53	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.581	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353464/suppl/GSM2353464_A52084400939213081815420934611018.CEL.gz	0			GSM2353464	GSM2353465_A52084400939235091415421177247078.CEL	"SUBJ.0377, SLE, baseline"	GSM2353465	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.1041095890411	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0377	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 172	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.748	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.102	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353465/suppl/GSM2353465_A52084400939235091415421177247078.CEL.gz	0	Reanalyzed by: GSM2351327		GSM2353465	GSM2353466_A52084400939233091415421177246890.CEL	"SUBJ.0377, SLE, week16"	GSM2353466	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.1041095890411	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0377	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 172	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.748	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.102	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353466/suppl/GSM2353466_A52084400939233091415421177246890.CEL.gz	0			GSM2353466	GSM2353467_A52084400939232091415421177246861.CEL	"SUBJ.0377, SLE, week52"	GSM2353467	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.1041095890411	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0377	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 172	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.748	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.102	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353467/suppl/GSM2353467_A52084400939232091415421177246861.CEL.gz	0			GSM2353467	GSM2353468_A52084400939113082215421026196585.CEL	"SUBJ.1742, SLE, baseline"	GSM2353468	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.6438356164383	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1742	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.93	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.145	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353468/suppl/GSM2353468_A52084400939113082215421026196585.CEL.gz	0	Reanalyzed by: GSM2351383		GSM2353468	GSM2353469_A52084400939115082215421026196670.CEL	"SUBJ.1742, SLE, week16"	GSM2353469	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.6438356164383	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1742	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.93	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.145	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353469/suppl/GSM2353469_A52084400939115082215421026196670.CEL.gz	0			GSM2353469	GSM2353470_A52084400939115082215421026196662.CEL	"SUBJ.1742, SLE, week52"	GSM2353470	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.6438356164383	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1742	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.93	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.145	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353470/suppl/GSM2353470_A52084400939115082215421026196662.CEL.gz	0			GSM2353470	GSM2353471_A52084400940550091515421247348615.CEL	"SUBJ.0231, SLE, baseline"	GSM2353471	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.6602739726027	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0231	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 102	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.19	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.24	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353471/suppl/GSM2353471_A52084400940550091515421247348615.CEL.gz	0	Reanalyzed by: GSM2351521		GSM2353471	GSM2353472_A52084400939232091415421177246832.CEL	"SUBJ.0231, SLE, week16"	GSM2353472	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.6602739726027	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0231	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 102	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.19	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.24	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353472/suppl/GSM2353472_A52084400939232091415421177246832.CEL.gz	0			GSM2353472	GSM2353473_A52084400940550091515421247348589.CEL	"SUBJ.0231, SLE, week52"	GSM2353473	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 24.6602739726027	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0231	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 102	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.19	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.24	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353473/suppl/GSM2353473_A52084400940550091515421247348589.CEL.gz	0			GSM2353473	GSM2353474_A52084400939115082215421026196666.CEL	"SUBJ.0465, SLE, baseline"	GSM2353474	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.131506849315	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0465	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 144	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.853	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.153	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353474/suppl/GSM2353474_A52084400939115082215421026196666.CEL.gz	0	Reanalyzed by: GSM2351060		GSM2353474	GSM2353475_A52084400939116082215421026196728.CEL	"SUBJ.0465, SLE, week16"	GSM2353475	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.131506849315	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0465	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 144	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.853	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.153	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353475/suppl/GSM2353475_A52084400939116082215421026196728.CEL.gz	0			GSM2353475	GSM2353476_A52084400939907082115420971516281.CEL	"SUBJ.0465, SLE, week52"	GSM2353476	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.131506849315	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0465	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 144	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.853	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.153	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353476/suppl/GSM2353476_A52084400939907082115420971516281.CEL.gz	0			GSM2353476	GSM2353477_A52084400939234091415421177246983.CEL	"SUBJ.0509, SLE, baseline"	GSM2353477	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.4684931506849	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0509	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: multiple	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 32	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.076	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353477/suppl/GSM2353477_A52084400939234091415421177246983.CEL.gz	0	Reanalyzed by: GSM2351630		GSM2353477	GSM2353478_A52084400939233091415421177246913.CEL	"SUBJ.0509, SLE, week16"	GSM2353478	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.4684931506849	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0509	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: multiple	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 32	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.076	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353478/suppl/GSM2353478_A52084400939233091415421177246913.CEL.gz	0			GSM2353478	GSM2353479_A52084400939233091415421177246893.CEL	"SUBJ.0509, SLE, week52"	GSM2353479	sledai_at_baseline: 20	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.4684931506849	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0509	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: multiple	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 32	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.076	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353479/suppl/GSM2353479_A52084400939233091415421177246893.CEL.gz	0			GSM2353479	GSM2353480_A52084400939853091415421246947206.CEL	"SUBJ.1238, SLE, baseline"	GSM2353480	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.9726775956284	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1238	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: asian	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.34	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.177	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353480/suppl/GSM2353480_A52084400939853091415421246947206.CEL.gz	0	Reanalyzed by: GSM2352464		GSM2353480	GSM2353481_A52084400939854091415421246947261.CEL	"SUBJ.1238, SLE, week16"	GSM2353481	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.9726775956284	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1238	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: asian	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.34	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.177	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353481/suppl/GSM2353481_A52084400939854091415421246947261.CEL.gz	0			GSM2353481	GSM2353482_A52084400939116082215421026196757.CEL	"SUBJ.1238, SLE, week52"	GSM2353482	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.9726775956284	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1238	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: asian	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 39	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.34	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.177	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353482/suppl/GSM2353482_A52084400939116082215421026196757.CEL.gz	0			GSM2353482	GSM2353483_A52084400940549091515421247348538.CEL	"SUBJ.0474, SLE, baseline"	GSM2353483	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.9344262295082	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0474	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 10	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.205	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353483/suppl/GSM2353483_A52084400940549091515421247348538.CEL.gz	0	Reanalyzed by: GSM2351734		GSM2353483	GSM2353484_A52084400940551091515421247348656.CEL	"SUBJ.0474, SLE, week16"	GSM2353484	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.9344262295082	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0474	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 10	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.205	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353484/suppl/GSM2353484_A52084400940551091515421247348656.CEL.gz	0			GSM2353484	GSM2353485_A52084400939234091415421177246970.CEL	"SUBJ.0474, SLE, week52"	GSM2353485	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.9344262295082	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0474	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 10	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.13	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.205	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353485/suppl/GSM2353485_A52084400939234091415421177246970.CEL.gz	0			GSM2353485	GSM2353486_A52084400940069100715421373649367.CEL	"SUBJ.1610, SLE, baseline"	GSM2353486	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.7021857923497	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1610	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.816	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.18	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353486/suppl/GSM2353486_A52084400940069100715421373649367.CEL.gz	0	Reanalyzed by: GSM2351623		GSM2353486	GSM2353487_A52084400940081100815421437950418.CEL	"SUBJ.1610, SLE, week16"	GSM2353487	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.7021857923497	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1610	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.816	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.18	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353487/suppl/GSM2353487_A52084400940081100815421437950418.CEL.gz	0			GSM2353487	GSM2353488_A52084400940081100815421437950423.CEL	"SUBJ.1610, SLE, week52"	GSM2353488	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.7021857923497	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1610	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 147	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.816	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.18	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353488/suppl/GSM2353488_A52084400940081100815421437950423.CEL.gz	0			GSM2353488	GSM2353489_A52084400939852091415421246947159.CEL	"SUBJ.1239, SLE, baseline"	GSM2353489	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.0547945205479	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1239	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 97	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.691	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353489/suppl/GSM2353489_A52084400939852091415421246947159.CEL.gz	0	Reanalyzed by: GSM2351866		GSM2353489	GSM2353490_A52084400939854091415421246947285.CEL	"SUBJ.1239, SLE, week16"	GSM2353490	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.0547945205479	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1239	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 97	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.691	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353490/suppl/GSM2353490_A52084400939854091415421246947285.CEL.gz	0			GSM2353490	GSM2353491_A52084400939855091415421246947321.CEL	"SUBJ.1239, SLE, week52"	GSM2353491	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.0547945205479	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1239	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 97	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.691	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353491/suppl/GSM2353491_A52084400939855091415421246947321.CEL.gz	0			GSM2353491	GSM2353492_A52084400939846091515421247126642.CEL	"SUBJ.0455, SLE, baseline"	GSM2353492	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 56.5890410958904	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0455	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.77	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.317	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353492/suppl/GSM2353492_A52084400939846091515421247126642.CEL.gz	0	Reanalyzed by: GSM2352686		GSM2353492	GSM2353493_A52084400940546091515421247226877.CEL	"SUBJ.0455, SLE, week52"	GSM2353493	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 56.5890410958904	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0455	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.77	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.317	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353493/suppl/GSM2353493_A52084400940546091515421247226877.CEL.gz	0			GSM2353493	GSM2353494_A52084400940067100715421373649247.CEL	"SUBJ.1389, SLE, baseline"	GSM2353494	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.4712328767123	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1389	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.505	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353494/suppl/GSM2353494_A52084400940067100715421373649247.CEL.gz	0	Reanalyzed by: GSM2351043		GSM2353494	GSM2353495_A52084400940067100715421373649237.CEL	"SUBJ.1389, SLE, week16"	GSM2353495	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.4712328767123	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1389	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.505	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353495/suppl/GSM2353495_A52084400940067100715421373649237.CEL.gz	0			GSM2353495	GSM2353496_A52084400940067100715421373649241.CEL	"SUBJ.1389, SLE, week52"	GSM2353496	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 20.4712328767123	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1389	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.505	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353496/suppl/GSM2353496_A52084400940067100715421373649241.CEL.gz	0			GSM2353496	GSM2353497_A52084400939114082215421026196639.CEL	"SUBJ.0911, SLE, baseline"	GSM2353497	sledai_at_baseline: 17	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.8688524590164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0911	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 259	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.065	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353497/suppl/GSM2353497_A52084400939114082215421026196639.CEL.gz	0	Reanalyzed by: GSM2352660		GSM2353497	GSM2353498_A52084400939213081815420934611021.CEL	"SUBJ.0911, SLE, week16"	GSM2353498	sledai_at_baseline: 17	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.8688524590164	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0911	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 259	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.065	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353498/suppl/GSM2353498_A52084400939213081815420934611021.CEL.gz	0			GSM2353498	GSM2353499_A52084400939114082215421026196638.CEL	"SUBJ.0911, SLE, week52"	GSM2353499	sledai_at_baseline: 17	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.8688524590164	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0911	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 259	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.12	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.065	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353499/suppl/GSM2353499_A52084400939114082215421026196638.CEL.gz	0			GSM2353499	GSM2353500_A52084400940659100115421372840961.CEL	"SUBJ.1341, SLE, baseline"	GSM2353500	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.186301369863	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1341	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 75	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.143	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353500/suppl/GSM2353500_A52084400940659100115421372840961.CEL.gz	0	Reanalyzed by: GSM2351000		GSM2353500	GSM2353501_A52084400940659100115421372840966.CEL	"SUBJ.1341, SLE, week16"	GSM2353501	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.186301369863	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1341	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 75	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.143	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353501/suppl/GSM2353501_A52084400940659100115421372840966.CEL.gz	0			GSM2353501	GSM2353502_A52084400940659100115421372840971.CEL	"SUBJ.1341, SLE, week52"	GSM2353502	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 26.186301369863	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1341	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 75	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.1	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.143	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353502/suppl/GSM2353502_A52084400940659100115421372840971.CEL.gz	0			GSM2353502	GSM2353503_A52084400939232091415421177246834.CEL	"SUBJ.1475, SLE, baseline"	GSM2353503	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8743169398907	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1475	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.958	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.143	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353503/suppl/GSM2353503_A52084400939232091415421177246834.CEL.gz	0	Reanalyzed by: GSM2352498		GSM2353503	GSM2353504_A52084400940549091515421247348558.CEL	"SUBJ.1475, SLE, week16"	GSM2353504	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8743169398907	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1475	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.958	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.143	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353504/suppl/GSM2353504_A52084400940549091515421247348558.CEL.gz	0			GSM2353504	GSM2353505_A52084400940549091515421247348549.CEL	"SUBJ.1475, SLE, week52"	GSM2353505	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 37.8743169398907	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1475	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.958	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.143	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353505/suppl/GSM2353505_A52084400940549091515421247348549.CEL.gz	0			GSM2353505	GSM2353506_A52084400939232091415421177246839.CEL	"SUBJ.1010, SLE, baseline"	GSM2353506	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.6027397260274	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1010	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.685	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.083	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353506/suppl/GSM2353506_A52084400939232091415421177246839.CEL.gz	0	Reanalyzed by: GSM2352507		GSM2353506	GSM2353507_A52084400939235091415421177247107.CEL	"SUBJ.1010, SLE, week16"	GSM2353507	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.6027397260274	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1010	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.685	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.083	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353507/suppl/GSM2353507_A52084400939235091415421177247107.CEL.gz	0			GSM2353507	GSM2353508_A52084400939233091415421177246896.CEL	"SUBJ.1010, SLE, week52"	GSM2353508	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.6027397260274	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1010	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.685	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.083	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353508/suppl/GSM2353508_A52084400939233091415421177246896.CEL.gz	0			GSM2353508	GSM2353509_A52084400939853091415421246947213.CEL	"SUBJ.1785, SLE, baseline"	GSM2353509	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.6273972602739	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1785	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.948	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353509/suppl/GSM2353509_A52084400939853091415421246947213.CEL.gz	0	Reanalyzed by: GSM2352020		GSM2353509	GSM2353510_A52084400939855091415421246947348.CEL	"SUBJ.1785, SLE, week16"	GSM2353510	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.6273972602739	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1785	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.948	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353510/suppl/GSM2353510_A52084400939855091415421246947348.CEL.gz	0			GSM2353510	GSM2353511_A52084400939232091415421177246827.CEL	"SUBJ.1785, SLE, week52"	GSM2353511	sledai_at_baseline: 18	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.6273972602739	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1785	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.948	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353511/suppl/GSM2353511_A52084400939232091415421177246827.CEL.gz	0			GSM2353511	GSM2353512_A52084400939920091515421247126502.CEL	"SUBJ.0913, SLE, baseline"	GSM2353512	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.9699453551912	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0913	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 174	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.91	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.115	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353512/suppl/GSM2353512_A52084400939920091515421247126502.CEL.gz	0	Reanalyzed by: GSM2351469		GSM2353512	GSM2353513_A52084400940656100115421372840774.CEL	"SUBJ.0913, SLE, week16"	GSM2353513	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.9699453551912	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0913	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 174	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.91	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.115	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353513/suppl/GSM2353513_A52084400940656100115421372840774.CEL.gz	0			GSM2353513	GSM2353514_A52084400940651100115421364640609.CEL	"SUBJ.0913, SLE, week52"	GSM2353514	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 52.9699453551912	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0913	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 174	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.91	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.115	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353514/suppl/GSM2353514_A52084400940651100115421364640609.CEL.gz	0			GSM2353514	GSM2353515_A52084400939232091415421177246868.CEL	"SUBJ.1554, SLE, baseline"	GSM2353515	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.6639344262295	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1554	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.854	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353515/suppl/GSM2353515_A52084400939232091415421177246868.CEL.gz	0	Reanalyzed by: GSM2350995		GSM2353515	GSM2353516_A52084400939235091415421177247100.CEL	"SUBJ.1554, SLE, week16"	GSM2353516	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.6639344262295	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1554	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.854	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353516/suppl/GSM2353516_A52084400939235091415421177247100.CEL.gz	0			GSM2353516	GSM2353517_A52084400939233091415421177246915.CEL	"SUBJ.1554, SLE, week52"	GSM2353517	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.6639344262295	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1554	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 9	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.854	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.025	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353517/suppl/GSM2353517_A52084400939233091415421177246915.CEL.gz	0			GSM2353517	GSM2353518_A52084400940545091515421247226798.CEL	"SUBJ.0599, SLE, baseline"	GSM2353518	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.5698630136986	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0599	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 40	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.38	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.362	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353518/suppl/GSM2353518_A52084400940545091515421247226798.CEL.gz	0	Reanalyzed by: GSM2352278		GSM2353518	GSM2353519_A52084400939921091515421247126575.CEL	"SUBJ.0599, SLE, week16"	GSM2353519	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.5698630136986	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0599	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 40	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.38	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.362	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353519/suppl/GSM2353519_A52084400939921091515421247126575.CEL.gz	0			GSM2353519	GSM2353520_A52084400939920091515421247126510.CEL	"SUBJ.0599, SLE, week52"	GSM2353520	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 53.5698630136986	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0599	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 40	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.38	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.362	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353520/suppl/GSM2353520_A52084400939920091515421247126510.CEL.gz	0			GSM2353520	GSM2353521_A52084400939920091515421247126489.CEL	"SUBJ.1416, SLE, baseline"	GSM2353521	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.2410958904109	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1416	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.37	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.263	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353521/suppl/GSM2353521_A52084400939920091515421247126489.CEL.gz	0	Reanalyzed by: GSM2350975		GSM2353521	GSM2353522_A52084400939846091515421247126644.CEL	"SUBJ.1416, SLE, week16"	GSM2353522	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.2410958904109	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1416	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.37	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.263	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353522/suppl/GSM2353522_A52084400939846091515421247126644.CEL.gz	0			GSM2353522	GSM2353523_A52084400939847091515421247126703.CEL	"SUBJ.1416, SLE, week52"	GSM2353523	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.2410958904109	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1416	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 11	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.37	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.263	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353523/suppl/GSM2353523_A52084400939847091515421247126703.CEL.gz	0			GSM2353523	GSM2353524_A52084400940659100115421372840954.CEL	"SUBJ.0342, SLE, baseline"	GSM2353524	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.7732240437158	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0342	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 17	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.139	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353524/suppl/GSM2353524_A52084400940659100115421372840954.CEL.gz	0	Reanalyzed by: GSM2350960		GSM2353524	GSM2353525_A52084400940659100115421372840964.CEL	"SUBJ.0342, SLE, week16"	GSM2353525	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.7732240437158	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0342	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 17	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.139	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353525/suppl/GSM2353525_A52084400940659100115421372840964.CEL.gz	0			GSM2353525	GSM2353526_A52084400940656100115421372840797.CEL	"SUBJ.0342, SLE, week52"	GSM2353526	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 47.7732240437158	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0342	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 17	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.06	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.139	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353526/suppl/GSM2353526_A52084400940656100115421372840797.CEL.gz	0			GSM2353526	GSM2353527_A52084400939114082215421026196624.CEL	"SUBJ.1422, SLE, baseline"	GSM2353527	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 54.2054794520548	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1422	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353527/suppl/GSM2353527_A52084400939114082215421026196624.CEL.gz	0	Reanalyzed by: GSM2352277		GSM2353527	GSM2353528_A52084400939212081815420934610960.CEL	"SUBJ.1422, SLE, week16"	GSM2353528	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 54.2054794520548	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1422	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353528/suppl/GSM2353528_A52084400939212081815420934610960.CEL.gz	0			GSM2353528	GSM2353529_A52084400939115082215421026196681.CEL	"SUBJ.1422, SLE, week52"	GSM2353529	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 54.2054794520548	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1422	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.216	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353529/suppl/GSM2353529_A52084400939115082215421026196681.CEL.gz	0			GSM2353529	GSM2353530_A52084400939845091415421247047568.CEL	"SUBJ.0929, SLE, baseline"	GSM2353530	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.7732240437158	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0929	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 211	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.896	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.109	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353530/suppl/GSM2353530_A52084400939845091415421247047568.CEL.gz	0	Reanalyzed by: GSM2352037		GSM2353530	GSM2353531_A52084400939231091315421177046190.CEL	"SUBJ.0929, SLE, week16"	GSM2353531	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.7732240437158	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0929	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 211	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.896	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.109	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353531/suppl/GSM2353531_A52084400939231091315421177046190.CEL.gz	0			GSM2353531	GSM2353532_A52084400939844091415421247047504.CEL	"SUBJ.0929, SLE, week52"	GSM2353532	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 42.7732240437158	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0929	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 211	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.896	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.109	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353532/suppl/GSM2353532_A52084400939844091415421247047504.CEL.gz	0			GSM2353532	GSM2353533_A52084400939113082215421026196553.CEL	"SUBJ.1168, SLE, baseline"	GSM2353533	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.5287671232876	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1168	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 19	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.235	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353533/suppl/GSM2353533_A52084400939113082215421026196553.CEL.gz	0	Reanalyzed by: GSM2351380		GSM2353533	GSM2353534_A52084400939115082215421026196664.CEL	"SUBJ.1168, SLE, week16"	GSM2353534	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.5287671232876	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1168	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 19	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.235	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353534/suppl/GSM2353534_A52084400939115082215421026196664.CEL.gz	0			GSM2353534	GSM2353535_A52084400939115082215421026196687.CEL	"SUBJ.1168, SLE, week52"	GSM2353535	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.5287671232876	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1168	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 19	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.235	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353535/suppl/GSM2353535_A52084400939115082215421026196687.CEL.gz	0			GSM2353535	GSM2353536_A52084400940549091515421247348536.CEL	"SUBJ.1472, SLE, baseline"	GSM2353536	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8876712328767	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1472	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 168	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.165	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353536/suppl/GSM2353536_A52084400940549091515421247348536.CEL.gz	0	Reanalyzed by: GSM2351873		GSM2353536	GSM2353537_A52084400940549091515421247348570.CEL	"SUBJ.1472, SLE, week16"	GSM2353537	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8876712328767	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1472	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 168	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.165	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353537/suppl/GSM2353537_A52084400940549091515421247348570.CEL.gz	0			GSM2353537	GSM2353538_A52084400940549091515421247348568.CEL	"SUBJ.1472, SLE, week52"	GSM2353538	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 25.8876712328767	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1472	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 168	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.14	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.165	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353538/suppl/GSM2353538_A52084400940549091515421247348568.CEL.gz	0			GSM2353538	GSM2353539_A52084400939271081315420891403921.CEL	"SUBJ.1082, SLE, baseline"	GSM2353539	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.8524590163934	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1082	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 148	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.747	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.168	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353539/suppl/GSM2353539_A52084400939271081315420891403921.CEL.gz	0	Reanalyzed by: GSM2351417		GSM2353539	GSM2353540_A52084400939272081315420891403982.CEL	"SUBJ.1082, SLE, week16"	GSM2353540	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.8524590163934	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1082	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 148	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.747	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.168	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353540/suppl/GSM2353540_A52084400939272081315420891403982.CEL.gz	0			GSM2353540	GSM2353541_A52084400939213081815420934611050.CEL	"SUBJ.1082, SLE, week52"	GSM2353541	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 32.8524590163934	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1082	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 148	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.747	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.168	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353541/suppl/GSM2353541_A52084400939213081815420934611050.CEL.gz	0			GSM2353541	GSM2353542_A52084400940067100715421373649252.CEL	"SUBJ.0523, SLE, baseline"	GSM2353542	sledai_at_baseline: 24	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.6493150684931	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0523	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.324	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.089	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353542/suppl/GSM2353542_A52084400940067100715421373649252.CEL.gz	0	Reanalyzed by: GSM2351155		GSM2353542	GSM2353543_A52084400940080100815421437950357.CEL	"SUBJ.0523, SLE, week16"	GSM2353543	sledai_at_baseline: 24	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.6493150684931	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0523	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.324	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.089	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353543/suppl/GSM2353543_A52084400940080100815421437950357.CEL.gz	0			GSM2353543	GSM2353544_A52084400940080100815421437950332.CEL	"SUBJ.0523, SLE, week52"	GSM2353544	sledai_at_baseline: 24	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.6493150684931	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0523	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.324	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.089	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353544/suppl/GSM2353544_A52084400940080100815421437950332.CEL.gz	0			GSM2353544	GSM2353545_A52084400940544091515421247226757.CEL	"SUBJ.0351, SLE, baseline"	GSM2353545	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.8688524590164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0351	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 67	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.831	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353545/suppl/GSM2353545_A52084400940544091515421247226757.CEL.gz	0	Reanalyzed by: GSM2351117		GSM2353545	GSM2353546_A52084400940546091515421247226887.CEL	"SUBJ.0351, SLE, week16"	GSM2353546	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.8688524590164	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0351	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 67	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.831	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353546/suppl/GSM2353546_A52084400940546091515421247226887.CEL.gz	0			GSM2353546	GSM2353547_A52084400940544091515421247226747.CEL	"SUBJ.0351, SLE, week52"	GSM2353547	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 33.8688524590164	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0351	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Male	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 67	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.831	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.21	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353547/suppl/GSM2353547_A52084400940544091515421247226747.CEL.gz	0			GSM2353547	GSM2353548_A52084400940546091515421247226873.CEL	"SUBJ.0450, SLE, baseline"	GSM2353548	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.6639344262295	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0450	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 7	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.26	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.221	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353548/suppl/GSM2353548_A52084400940546091515421247226873.CEL.gz	0	Reanalyzed by: GSM2352234		GSM2353548	GSM2353549_A52084400940545091515421247226795.CEL	"SUBJ.0450, SLE, week16"	GSM2353549	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.6639344262295	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0450	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 7	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.26	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.221	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353549/suppl/GSM2353549_A52084400940545091515421247226795.CEL.gz	0			GSM2353549	GSM2353550_A52084400939232091415421177246848.CEL	"SUBJ.0450, SLE, week52"	GSM2353550	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.6639344262295	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0450	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 7	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.26	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.221	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353550/suppl/GSM2353550_A52084400939232091415421177246848.CEL.gz	0			GSM2353550	GSM2353551_A52084400939213081815420934611016.CEL	"SUBJ.0356, SLE, baseline"	GSM2353551	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.7814207650273	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0356	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 55	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.95	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.142	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353551/suppl/GSM2353551_A52084400939213081815420934611016.CEL.gz	0	Reanalyzed by: GSM2352123		GSM2353551	GSM2353552_A52084400939272081315420891403985.CEL	"SUBJ.0356, SLE, week16"	GSM2353552	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.7814207650273	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0356	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 55	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.95	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.142	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353552/suppl/GSM2353552_A52084400939272081315420891403985.CEL.gz	0			GSM2353552	GSM2353553_A52084400939212081815420934610957.CEL	"SUBJ.0356, SLE, week52"	GSM2353553	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.7814207650273	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0356	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 55	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.95	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.142	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353553/suppl/GSM2353553_A52084400939212081815420934610957.CEL.gz	0			GSM2353553	GSM2353554_A52084400939852091415421246947123.CEL	"SUBJ.0878, SLE, baseline"	GSM2353554	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.4575342465753	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0878	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.953	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.113	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353554/suppl/GSM2353554_A52084400939852091415421246947123.CEL.gz	0	Reanalyzed by: GSM2351176		GSM2353554	GSM2353555_A52084400939843091415421247047462.CEL	"SUBJ.0878, SLE, week16"	GSM2353555	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.4575342465753	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0878	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.953	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.113	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353555/suppl/GSM2353555_A52084400939843091415421247047462.CEL.gz	0			GSM2353555	GSM2353556_A52084400939854091415421246947247.CEL	"SUBJ.0878, SLE, week52"	GSM2353556	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 43.4575342465753	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0878	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.953	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.113	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353556/suppl/GSM2353556_A52084400939854091415421246947247.CEL.gz	0			GSM2353556	GSM2353557_A52084400939235091415421177247103.CEL	"SUBJ.0438, SLE, baseline"	GSM2353557	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 22.9506849315068	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0438	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353557/suppl/GSM2353557_A52084400939235091415421177247103.CEL.gz	0	Reanalyzed by: GSM2352043		GSM2353557	GSM2353558_A52084400940545091515421247226811.CEL	"SUBJ.0438, SLE, week16"	GSM2353558	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 22.9506849315068	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0438	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353558/suppl/GSM2353558_A52084400940545091515421247226811.CEL.gz	0			GSM2353558	GSM2353559_A52084400940551091515421247348680.CEL	"SUBJ.0438, SLE, week52"	GSM2353559	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 22.9506849315068	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0438	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.04	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.16	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353559/suppl/GSM2353559_A52084400940551091515421247348680.CEL.gz	0			GSM2353559	GSM2353560_A52084400940082100815421437950470.CEL	"SUBJ.1368, SLE, baseline"	GSM2353560	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.8743169398907	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1368	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.879	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.129	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353560/suppl/GSM2353560_A52084400940082100815421437950470.CEL.gz	0	Reanalyzed by: GSM2352530		GSM2353560	GSM2353561_A52084400940082100815421437950445.CEL	"SUBJ.1368, SLE, week16"	GSM2353561	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.8743169398907	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1368	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.879	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.129	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353561/suppl/GSM2353561_A52084400940082100815421437950445.CEL.gz	0			GSM2353561	GSM2353562_A52084400940082100815421437950474.CEL	"SUBJ.1368, SLE, week52"	GSM2353562	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.8743169398907	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1368	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.879	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.129	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353562/suppl/GSM2353562_A52084400940082100815421437950474.CEL.gz	0			GSM2353562	GSM2353563_A52084400939920091515421247126494.CEL	"SUBJ.1180, SLE, baseline"	GSM2353563	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.9643835616438	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1180	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.275	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353563/suppl/GSM2353563_A52084400939920091515421247126494.CEL.gz	0	Reanalyzed by: GSM2351917		GSM2353563	GSM2353564_A52084400939846091515421247126623.CEL	"SUBJ.1180, SLE, week16"	GSM2353564	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.9643835616438	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1180	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.275	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353564/suppl/GSM2353564_A52084400939846091515421247126623.CEL.gz	0			GSM2353564	GSM2353565_A52084400939847091515421247126696.CEL	"SUBJ.1180, SLE, week52"	GSM2353565	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 40.9643835616438	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1180	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.275	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353565/suppl/GSM2353565_A52084400939847091515421247126696.CEL.gz	0			GSM2353565	GSM2353566_A52084400939113082215421026196577.CEL	"SUBJ.0908, SLE, baseline"	GSM2353566	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.5643835616438	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0908	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.168	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353566/suppl/GSM2353566_A52084400939113082215421026196577.CEL.gz	0	Reanalyzed by: GSM2352302		GSM2353566	GSM2353567_A52084400939114082215421026196640.CEL	"SUBJ.0908, SLE, week16"	GSM2353567	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.5643835616438	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0908	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.168	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353567/suppl/GSM2353567_A52084400939114082215421026196640.CEL.gz	0			GSM2353567	GSM2353568_A52084400939113082215421026196574.CEL	"SUBJ.0908, SLE, week52"	GSM2353568	sledai_at_baseline: 11	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 30.5643835616438	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0908	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 13	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.25	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.168	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353568/suppl/GSM2353568_A52084400939113082215421026196574.CEL.gz	0			GSM2353568	GSM2353569_A52084400939215081815420934611153.CEL	"SUBJ.0288, SLE, baseline"	GSM2353569	sledai_at_baseline: 24	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 21.7349726775956	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0288	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.131	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353569/suppl/GSM2353569_A52084400939215081815420934611153.CEL.gz	0	Reanalyzed by: GSM2351053		GSM2353569	GSM2353570_A52084400939213081815420934611025.CEL	"SUBJ.0288, SLE, week16"	GSM2353570	sledai_at_baseline: 24	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 21.7349726775956	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0288	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.131	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353570/suppl/GSM2353570_A52084400939213081815420934611025.CEL.gz	0			GSM2353570	GSM2353571_A52084400939272081315420891403984.CEL	"SUBJ.0047, SLE, baseline"	GSM2353571	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 60.0657534246575	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0047	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353571/suppl/GSM2353571_A52084400939272081315420891403984.CEL.gz	0	Reanalyzed by: GSM2350999		GSM2353571	GSM2353572_A52084400939269081315420891403784.CEL	"SUBJ.0047, SLE, week16"	GSM2353572	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 60.0657534246575	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0047	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353572/suppl/GSM2353572_A52084400939269081315420891403784.CEL.gz	0			GSM2353572	GSM2353573_A52084400939269081315420891403798.CEL	"SUBJ.0047, SLE, week52"	GSM2353573	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 60.0657534246575	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.0047	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.39	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.163	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353573/suppl/GSM2353573_A52084400939269081315420891403798.CEL.gz	0			GSM2353573	GSM2353574_A52084400939113082215421026196580.CEL	"SUBJ.0147, SLE, baseline"	GSM2353574	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9753424657534	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0147	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 217	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.77	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.077	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353574/suppl/GSM2353574_A52084400939113082215421026196580.CEL.gz	0	Reanalyzed by: GSM2352064		GSM2353574	GSM2353575_A52084400939113082215421026196548.CEL	"SUBJ.0147, SLE, week16"	GSM2353575	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9753424657534	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0147	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 217	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.77	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.077	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353575/suppl/GSM2353575_A52084400939113082215421026196548.CEL.gz	0			GSM2353575	GSM2353576_A52084400939116082215421026196744.CEL	"SUBJ.0147, SLE, week52"	GSM2353576	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 50.9753424657534	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0147	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 217	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.77	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.077	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353576/suppl/GSM2353576_A52084400939116082215421026196744.CEL.gz	0			GSM2353576	GSM2353577_A52084400939852091415421246947141.CEL	"SUBJ.0726, SLE, baseline"	GSM2353577	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.8715846994535	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0726	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.862	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.138	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353577/suppl/GSM2353577_A52084400939852091415421246947141.CEL.gz	0	Reanalyzed by: GSM2351510		GSM2353577	GSM2353578_A52084400939855091415421246947307.CEL	"SUBJ.0726, SLE, week16"	GSM2353578	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.8715846994535	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0726	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.862	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.138	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353578/suppl/GSM2353578_A52084400939855091415421246947307.CEL.gz	0			GSM2353578	GSM2353579_A52084400939855091415421246947330.CEL	"SUBJ.0726, SLE, week52"	GSM2353579	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 41.8715846994535	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.0726	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.862	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.138	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353579/suppl/GSM2353579_A52084400939855091415421246947330.CEL.gz	0			GSM2353579	GSM2353580_A52084400939215081815420934611158.CEL	"SUBJ.1779, SLE, baseline"	GSM2353580	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 60.2684931506849	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1779	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.16	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.229	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353580/suppl/GSM2353580_A52084400939215081815420934611158.CEL.gz	0	Reanalyzed by: GSM2351127		GSM2353580	GSM2353581_A52084400939215081815420934611159.CEL	"SUBJ.1779, SLE, week16"	GSM2353581	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 60.2684931506849	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1779	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.16	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.229	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353581/suppl/GSM2353581_A52084400939215081815420934611159.CEL.gz	0			GSM2353581	GSM2353582_A52084400939214081815420934611116.CEL	"SUBJ.1779, SLE, week52"	GSM2353582	sledai_at_baseline: 9	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 60.2684931506849	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1779	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: white	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 3	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.16	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.229	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353582/suppl/GSM2353582_A52084400939214081815420934611116.CEL.gz	0			GSM2353582	GSM2353583_A52084400939844091415421247047514.CEL	"SUBJ.1824, SLE, baseline"	GSM2353583	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.3561643835616	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1824	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 20	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.05	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.149	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353583/suppl/GSM2353583_A52084400939844091415421247047514.CEL.gz	0	Reanalyzed by: GSM2351512		GSM2353583	GSM2353584_A52084400939843091415421247047465.CEL	"SUBJ.1824, SLE, week16"	GSM2353584	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.3561643835616	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1824	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 20	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.05	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.149	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353584/suppl/GSM2353584_A52084400939843091415421247047465.CEL.gz	0			GSM2353584	GSM2353585_A52084400939843091415421247047453.CEL	"SUBJ.1824, SLE, week52"	GSM2353585	sledai_at_baseline: 12	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 39.3561643835616	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	Homo sapiens	subject_id: SUBJ.1824	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q2W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 20	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.05	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.149	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q2W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353585/suppl/GSM2353585_A52084400939843091415421247047453.CEL.gz	0			GSM2353585	GSM2353586_A52084400939116082215421026196739.CEL	"SUBJ.1509, SLE, baseline"	GSM2353586	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.3561643835616	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1509	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.568	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.091	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353586/suppl/GSM2353586_A52084400939116082215421026196739.CEL.gz	0	Reanalyzed by: GSM2352480		GSM2353586	GSM2353587_A52084400939113082215421026196559.CEL	"SUBJ.1509, SLE, week16"	GSM2353587	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.3561643835616	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1509	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.568	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.091	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353587/suppl/GSM2353587_A52084400939113082215421026196559.CEL.gz	0			GSM2353587	GSM2353588_A52084400939114082215421026196616.CEL	"SUBJ.1509, SLE, week52"	GSM2353588	sledai_at_baseline: 10	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 44.3561643835616	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1509	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: white	Sex: Female	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): L	c3_at_baseline (g/l): 0.568	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.091	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353588/suppl/GSM2353588_A52084400939114082215421026196616.CEL.gz	0			GSM2353588	GSM2353589_A52084400940068100715421373649306.CEL	"SUBJ.1011, SLE, baseline"	GSM2353589	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 56.0356164383561	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1011	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 17	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.16	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.37	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353589/suppl/GSM2353589_A52084400940068100715421373649306.CEL.gz	0	Reanalyzed by: GSM2351027		GSM2353589	GSM2353590_A52084400940069100715421373649352.CEL	"SUBJ.1011, SLE, week16"	GSM2353590	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 56.0356164383561	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1011	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 17	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.16	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.37	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353590/suppl/GSM2353590_A52084400940069100715421373649352.CEL.gz	0			GSM2353590	GSM2353591_A52084400940070100715421373649428.CEL	"SUBJ.1011, SLE, week52"	GSM2353591	sledai_at_baseline: 6	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 56.0356164383561	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.1011	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 17	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.16	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.37	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353591/suppl/GSM2353591_A52084400940070100715421373649428.CEL.gz	0			GSM2353591	GSM2353592_A52084400940067100715421373649215.CEL	"SUBJ.1510, SLE, baseline"	GSM2353592	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.3424657534246	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1510	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.999	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.054	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353592/suppl/GSM2353592_A52084400940067100715421373649215.CEL.gz	0	Reanalyzed by: GSM2352046		GSM2353592	GSM2353593_A52084400940080100815421437950338.CEL	"SUBJ.1510, SLE, week16"	GSM2353593	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.3424657534246	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1510	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.999	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.054	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353593/suppl/GSM2353593_A52084400940080100815421437950338.CEL.gz	0			GSM2353593	GSM2353594_A52084400940080100815421437950362.CEL	"SUBJ.1510, SLE, week52"	GSM2353594	sledai_at_baseline: 14	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 34.3424657534246	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1510	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: amer_ind_ak_native	Sex: Female	region: mex_ca_sa	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): 297	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 0.999	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): L	c4_at_baseline (g/l): 0.054	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353594/suppl/GSM2353594_A52084400940080100815421437950362.CEL.gz	0			GSM2353594	GSM2353595_A52084400939855091415421246947301.CEL	"SUBJ.0322, SLE, baseline"	GSM2353595	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.4383561643835	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.0322	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): --	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.186	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353595/suppl/GSM2353595_A52084400939855091415421246947301.CEL.gz	0	Reanalyzed by: GSM2352673		GSM2353595	GSM2353596_A52084400939852091415421246947168.CEL	"SUBJ.0322, SLE, week16"	GSM2353596	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.4383561643835	RNA	1	Blood sample from SLE subject at week16 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0322	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): --	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.186	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353596/suppl/GSM2353596_A52084400939852091415421246947168.CEL.gz	0			GSM2353596	GSM2353597_A52084400939855091415421246947320.CEL	"SUBJ.0322, SLE, week52"	GSM2353597	sledai_at_baseline: 8	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 46.4383561643835	RNA	1	Blood sample from SLE subject at week52 with Placebo treatment	Homo sapiens	subject_id: SUBJ.0322	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): Placebo	batch: ILLUMINATE-1	race: afr_amer	Sex: Female	region: us_can	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Positive	antidsdna_at_baseline (iu): --	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.01	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.186	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with Placebo treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353597/suppl/GSM2353597_A52084400939855091415421246947320.CEL.gz	0			GSM2353597	GSM2353598_A52084400940549091515421247348542.CEL	"SUBJ.1645, SLE, baseline"	GSM2353598	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.3616438356164	RNA	1	Blood sample from SLE subject at baseline	Homo sapiens	subject_id: SUBJ.1645	time: baseline	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 12	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.188	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at baseline	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353598/suppl/GSM2353598_A52084400940549091515421247348542.CEL.gz	0	Reanalyzed by: GSM2351248		GSM2353598	GSM2353599_A52084400939232091415421177246860.CEL	"SUBJ.1645, SLE, week16"	GSM2353599	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.3616438356164	RNA	1	Blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1645	time: week16	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 12	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.188	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week16 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353599/suppl/GSM2353599_A52084400939232091415421177246860.CEL.gz	0			GSM2353599	GSM2353600_A52084400940544091515421247226748.CEL	"SUBJ.1645, SLE, week52"	GSM2353600	sledai_at_baseline: 13	Public on Oct 25 2016	Oct 18 2016	Oct 25 2016	age_at_baseline: 48.3616438356164	RNA	1	Blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	Homo sapiens	subject_id: SUBJ.1645	time: week52	group: Systemic lupus erythematosus (SLE)	treatment (q2w=once in 2 weeks; q4w=once in 4 weeks): LY 120 mg Q4W	batch: ILLUMINATE-1	race: white	Sex: Male	region: europe	adna_at_baseline (anti-dsdna level: Negative < 30 IU; Positive  Š_Ç 30 IU): Negative	antidsdna_at_baseline (iu): 12	c3base (low < 0.9 g/l; normal >= 0.9 g/l; h = high): N	c3_at_baseline (g/l): 1.09	c4base (low < 0.1 g/l; normal >= 0.1 g/l; h = high): N	c4_at_baseline (g/l): 0.188	tissue: Blood	"A subset of SLE patients were treated with the BAFF/BLyS-blocking, fully-human IgG4 monoclonal antibody, tabalumab (120 mg Q2W or 120 mg Q4W) for 16 weeks or 52 weeks prior to RNA extraction."	total RNA	"Total RNA was extracted from whole blood (preserved in Tempus tubes) using the PerfectPureTM RNA Blood Kit as recommended by the manufacturer (Five Prime, South San Francisco, CA)."	biotin	Target preparation was performed according to Affymetrix WT Plus amplification protocol (www.affymetrix.com).	9606	The cDNA generated during the amplification step was used in a fragmentation and labeling reaction to generate target for hybridization to the Affymetrix HTA2.0 arrays	GeneChips were scanned using the Affymetrix GeneChip Scanner 3000 7G.	Gene expression measured in blood sample from SLE subject at week52 with LY 120 mg Q4W treatment	"HTA2.0 microarray pre-processing was performed. Probe level microarray data were summarized to two different levels, ""gene"" level and ""exon-group"" level. In both cases, the first two steps of the pre-processing were standard background correction and quantile normalization, as done in standard robust multi-array average (22). For the ""gene"" level analyses, data were then summarized by the sample effect estimated by robust regression (rlm function in the R MASS package) from a two-way ANOVA model with probe and sample effects. For the ""exon-group"" analysis (presented in the corresponding data matrix table), data were first summarized to the probeset level (as defined by Affymetrix) and low-expression probesets were filtered out as follows. An expression score was constructed for each probeset by computing the 80th percentile across all samples; probesets whose expression score was below the 95th percentile of the intronic normalization control probesets (normgene->intron) were discarded. The filtered probesets within a ""transcript cluster"" were then grouped using hierarchical clustering to form exon groups using the R hclust function. The distance metric between two probesets was defined as one minus the correlation of the pair. Probe level data were then summarized for each ""exon-group"" (cluster) using robust estimates of the sample effects as done in the ""gene"" level summarization."	GPL17586	"Robert,W,Hoffman"	hoffman_robert_w@lilly.com	1 317 651 4209	Lilly Bio-Medicines/Immunology	Eli Lilly and Company	Lilly Corporate Center	Indianapolis	IN	46285	USA	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM2353nnn/GSM2353600/suppl/GSM2353600_A52084400940544091515421247226748.CEL.gz	0			GSM2353600	